



Your live
EASL Campus
experience

THE

INTERNATIONAL

LIVER

CONGRESS™

BEATING LIVER DISEASE *together*

23-26 June 2021

**ACCEPTED
ABSTRACTS
OF THE FIRST ROUND**

#ILC2021

Abstract n°443

Category: Acute liver failure and drug induced liver injury

Title: SZN-043, a hepatocyte targeted R-spondin mimetic, induces hepatocyte proliferation in acute acetaminophen-induced liver injury model

Presenter: Mehaben Patel

Abstract n°537

Category: Acute liver failure and drug induced liver injury

Title: Protective effect of GOLM1 on acute liver failure in mice

Presenter: Linlan Qiao

Abstract n°559

Category: Acute liver failure and drug induced liver injury

Title: Chemokine receptor CCR5 and its corresponding chemokines contribute to virus-induced liver injury via conventional NK cells recruitment

Presenter: Tao Chen

Abstract n°679

Category: Acute liver failure and drug induced liver injury

Title: Development and validation of a noninvasive algorithm to predict significant fibrosis in patients with chronic drug-induced liver injury

Presenter: Dong Ji

Abstract n°712

Category: Acute liver failure and drug induced liver injury

Title: fibrinogen-like protein 2 promotes fulminant hepatitis by inducing neutrophil activation and neutrophil extracellular traps formation

Presenter: Xitang Li

Abstract n°1107

Category: Acute liver failure and drug induced liver injury

Title: Acute liver injury among patients with COVID-19 in a tertiary hospital

Presenter: Henry Winston Li

Abstract n°1185

Category: Acute liver failure and drug induced liver injury

Title: Magnesium homeostasis by Cyclin M4: a novel therapeutic mechanism in Acetaminophen-induced liver damage

Presenter: Irene González-Recio

Abstract n°1335

Category: Acute liver failure and drug induced liver injury

Title: Metabolomic predictive models in the diagnosis of drug-induced liver injury

Presenter: Daniel E. Di Zeo-Sánchez

Abstract n°1379

Category: Acute liver failure and drug induced liver injury

Title: CXCR3pos CD27pos CD161pos NK cells in autoimmune and drug induced liver injury position around lectin like transcript-1 expressing Kupffer cells and CD70pos dendritic cells

Presenter: Amber Bozward

Abstract n°1389

Category: Acute liver failure and drug induced liver injury

Title: Effect of corticosteroids in the outcome of drug-induced liver injury: a propensity score matched study

Presenter: Hao Niu

Abstract n°1406

Category: Acute liver failure and drug induced liver injury

Title: Comparison of gut microbiota composition between patients with drug-induced liver injury, other forms of liver injury and healthy controls

Presenter: Raul J. Andrade

Abstract n°1885

Category: Acute liver failure and drug induced liver injury

Title: ALKBH5-modified HMGB1-STING activation contributes to radiation-induced liver disease via innate immune response

Presenter: Genwen Chen

Abstract n°1947

Category: Acute liver failure and drug induced liver injury

Title: Etiology and clinical characteristics of acute hepatitis in South Korea: A prospective, multicenter Study

Presenter: Gwang Hyeon Choi

Abstract n°2122

Category: Acute liver failure and drug induced liver injury

Title: Decreased Overall Mortality and Mortality without Liver Transplantation with N-Acetylcysteine in Non-acetaminophen-induced Acute Liver Failure: A Systematic Review and Meta-Analysis

Presenter: Adrian Alick Bonghanoy

Abstract n°2178

Category: Acute liver failure and drug induced liver injury

Title: Low baseline cortisol but not delta cortisol relates to 28-day transplant-free survival in acute liver failure syndromes

Presenter: Sofia Roth

Abstract n°2203

Category: Acute liver failure and drug induced liver injury

Title: Diagnostic role of liver biopsy in patients with acute liver failure or acute liver injury

Presenter: Peter-Marton Hunyady

Abstract n°48

Category: Alcoholic liver disease

Title: Alcohol-related liver disease phenotype impacts survival after an acute variceal bleeding episode

Presenter: Ares Villagrasa

Abstract n°94

Category: Alcoholic liver disease

Title: Automated quantitation of histological features could predict mortality in patients with severe alcoholic hepatitis

Presenter: Luke D. Tyson

Abstract n°117

Category: Alcoholic liver disease

Title: Sulfated Steroids and Bile Acids and Dopamine Metabolites are Associated with Favorable Outcomes after Fecal Transplant in Alcohol Use Disorder

Presenter: Jasmohan S Bajaj

Abstract n°302

Category: Alcoholic liver disease

Title: Pharmacokinetics, Pharmacodynamics, and toxicology of SZN-043, a hepatocyte-targeted Wnt potentiator, in nonhuman primates

Presenter: Jay Tibbitts

Abstract n°345

Category: Alcoholic liver disease

Title: Alcoholic foamy degeneration: a singular clinical entity that mimics alcoholic hepatitis and may be distinguished by serum triglyceride levels

Presenter: Jordi Gratacós-Gines

Abstract n°433

Category: Alcoholic liver disease

Title: Drivers of outcome in compensated alcohol-related cirrhosis: a prospective study

Presenter: Alexandre Louvet

Abstract n°442

Category: Alcoholic liver disease

Title: SZN-043, a Hepatocyte-targeted-R-spondin mimetic, stimulates hepatocyte proliferation in an acute alcoholic hepatitis model

Presenter: Trevor Fisher

Abstract n°487

Category: Alcoholic liver disease

Title: Binge drinking induces an acute release of markers of hepatic fibrogenesis

Presenter: Nikolaj Torp

Abstract n°488

Category: Alcoholic liver disease

Title: Has the 5-year mortality of patients with alcoholic cirrhosis changed during the last 20 years ?

Presenter: Edeline Kaze

Abstract n°607

Category: Alcoholic liver disease

Title: Acamprosate for the treatment of alcohol use disorder may be safer than baclofen in patients with cirrhosis

Presenter: Luke D. Tyson

Abstract n°832

Category: Alcoholic liver disease

Title: Prevalence of steatosis and fibrosis in individuals with high-alcohol consumption assessed by FibroScan: real-world cohort study from the US population

Presenter: Naim Alkhouri

Abstract n°1099

Category: Alcoholic liver disease

Title: The alarming impact of COVID-19 pandemic on alcohol-related liver disease: a population-based Canadian study

Presenter: Abdel-Aziz Shaheen

Abstract n°1215

Category: Alcoholic liver disease

Title: Cell specific roles of MLKL in alcohol-associated liver disease

Presenter: Xiaoqin Wu

Abstract n°1293

Category: Alcoholic liver disease

Title: Neutrophil extracellular traps formation induced by alcohol generates a unique neutrophil subset with defective neutrophil functions causing liver damage in alcoholic hepatitis

Presenter: Yeonhee Cho

Abstract n°1375

Category: Alcoholic liver disease

Title: Self-reported interest in decreasing alcohol use in patients with alcohol-related liver disease: a national health survey

Presenter: Anna Kann

Abstract n°1541

Category: Alcoholic liver disease

Title: Potential underlying mechanisms in the immune response to COVID in obese heavy drinkers

Presenter: Marti Ortega-Ribera

Abstract n°1563

Category: Alcoholic liver disease

Title: Longer-term Outcome from Alcoholic Hepatitis: survival, re-admission rate and out-patient attendance after discharge

Presenter: Murray Foster

Abstract n°1619

Category: Alcoholic liver disease

Title: Lung infection impacts short-term survival in severe alcoholic hepatitis treated with steroids: results of a prospective monocenter study

Presenter: Line Carolle Ntandja Wandji

Abstract n°1623

Category: Alcoholic liver disease

Title: Treatment of alcohol withdrawal syndrome in patients with alcohol-related liver disease

Presenter: Alexander Doyle

Abstract n°1651

Category: Alcoholic liver disease

Title: Histological lesions can predict response to corticosteroids in patients with severe alcohol-related steatohepatitis

Presenter: Carolin Lackner

Abstract n°1654

Category: Alcoholic liver disease

Title: Changes in alcohol-related liver disease admissions over the time of minimum unit pricing of alcohol: the GRI Q4 study

Presenter: Sardar Chaudhary

Abstract n°1663

Category: Alcoholic liver disease

Title: Extracellular inflammasome components perpetuate inflammation in alcoholic hepatitis

Presenter: Marcelle de Carvalho Ribeiro

Abstract n°1708

Category: Alcoholic liver disease

Title: Hallmarks of neutrophil extracellular trap (NET) components in the course of alcoholic liver disease

Presenter: Anna Rycyk

Abstract n°1726

Category: Alcoholic liver disease

Title: Natural history of alcohol-related liver disease according to biopsy-proven fibrosis in a prospective study of 422 patients and 1,419 patient years

Presenter: Ditlev Rasmussen

Abstract n°1932

Category: Alcoholic liver disease

Title: Results of a screening program of liver fibrosis with transient elastography in subjects with alcohol use disorder

Presenter: Emma Avitabile

Abstract n°2028

Category: Alcoholic liver disease

Title: CXCL12-CXCR4 PATHWAY DRIVES HEPATOCYTE REPROGRAMMING IN ALCOHOLIC HEPATITIS

Presenter: Beatriz Aguilar-Bravo

Abstract n°2043

Category: Alcoholic liver disease

Title: The role of miR-873-5p in Alcohol-related Liver Disease

Presenter: Rubén Rodríguez Agudo

Abstract n°2158

Category: Alcoholic liver disease

Title: Interferon lambda 4 is associated with dysfunctional antibacterial immunity during alcohol-related liver disease

Presenter: Jennifer M Ryan

Abstract n°2185

Category: Alcoholic liver disease

Title: Human Precision Cut Liver Slices as a model of Alcohol-related Liver Disease: recapitulating disease progression in a dish.

Presenter: Elena Palma

Abstract n°2309

Category: Alcoholic liver disease

Title: Impact of the public health policies and alcohol-associated liver disease in Latin America: An ecological multi-national study

Presenter: Luis Antonio Diaz

Abstract n°2331

Category: Alcoholic liver disease

Title: Past hospital contacts due to alcohol do not predict fibrosis stage in alcohol-related liver disease. A study of alcohol diagnoses and morbidity in 18 years leading up to biopsy-proven liver fibrosis in 462 patients

Presenter: Ditlev Rasmussen

Abstract n°2341

Category: Alcoholic liver disease

Title: High oxidative stress in T cells and monocytes correlates with mortality from alcoholic hepatitis

Presenter: Huey Tan

Abstract n°2389

Category: Alcoholic liver disease

Title: Hospitalization Outcomes of Acute Alcoholic Hepatitis with Protein Energy Malnutrition - A nationwide Analysis

Presenter: Adnan Malik

Abstract n°2417

Category: Alcoholic liver disease

Title: Impact of COVID-19 pandemic on liver transplantation and alcohol-associated liver disease in the United States

Presenter: George Cholankeril

Abstract n°309

Category: Cirrhosis and its complications (1): Portal Hypertension

Title: Systemic inflammation promotes liver fibrogenesis and matrix turnover in patients with advanced chronic liver disease

Presenter: Benedikt Simbrunner

Abstract n°310

Category: Cirrhosis and its complications (1): Portal Hypertension

Title: Von Willebrand Factor (VWF) propeptide levels are similarly accurate for assessing portal hypertension as compared to VWF antigen

Presenter: Ida Villesen

Abstract n°532

Category: Cirrhosis and its complications (1): Portal Hypertension

Title: Clinical outcomes of cirrhotic patients with dysregulated hormones of vascular homeostasis

Presenter: Lukas Hartl

Abstract n°560

Category: Cirrhosis and its complications (1): Portal Hypertension

Title: Decreasing VWF levels upon NSBB therapy indicate a reduced risk of further decompensation, ACLF and death

Presenter: Mathias Jachs

Abstract n°755

Category: Cirrhosis and its complications (1): Portal Hypertension

Title: Relationship between genotype and severe hepatic phenotype in compound heterozygous Cystic Fibrosis patients with one F508del CFTR mutation

Presenter: Suzan Duursma

Abstract n°1032

Category: Cirrhosis and its complications (1): Portal Hypertension

Title: Impact of hyponatremia on morbidity, mortality and resource utilization in portal hypertensive ascites: a nationwide analysis

Presenter: Joseph Alukal

Abstract n°1038

Category: Cirrhosis and its complications (1): Portal Hypertension

Title: A scoring model to predict mortality in hospitalized patients with decompensated cirrhosis and hyponatremia

Presenter: Joseph Alukal

Abstract n°1040

Category: Cirrhosis and its complications (1): Portal Hypertension

Title: The natural history of advanced chronic liver disease defined by transient elastography

Presenter: Jessica Shearer

Abstract n°1064

Category: Cirrhosis and its complications (1): Portal Hypertension

Title: Emergency room care is essential in improving outcomes of decompensated cirrhosis patients: A Canadian experience

Presenter: Jesse Stach

Abstract n°1094

Category: Cirrhosis and its complications (1): Portal Hypertension

Title: Timing of endoscopy for acute variceal bleeding in patients with cirrhosis (CHESS1905): a nationwide cohort study

Presenter: Yifei Huang

Abstract n°1103

Category: Cirrhosis and its complications (1): Portal Hypertension

Title: In-hospital mortality after surgery in patients with liver cirrhosis: A nationwide study of 1,662,887 patients

Presenter: Jeong-Ju Yoo

Abstract n°1146

Category: Cirrhosis and its complications (1): Portal Hypertension

Title: Metamizole intake is associated with acute kidney injury and a higher mortality in patients with decompensated liver cirrhosis

Presenter: Tammo Lambert Tergast

Abstract n°1151

Category: Cirrhosis and its complications (1): Portal Hypertension

Title: Stratifying the risk of variceal bleeding by non-invasive tools in patients with compensated advanced chronic liver disease: A decision curve analysis

Presenter: Sanchit Sharma

Abstract n°1152

Category: Cirrhosis and its complications (1): Portal Hypertension

Title: Risk stratification based on liver stiffness and platelets for decompensation events in patients with compensated cirrhosis

Presenter: Ruiling He

Abstract n°1230

Category: Cirrhosis and its complications (1): Portal Hypertension

Title: FIB-4 improves LSM-based prediction of clinical decompensation in overweight or obese patients with compensated advanced chronic liver disease

Presenter: Yuly Paulin Mendoza

Abstract n°1236

Category: Cirrhosis and its complications (1): Portal Hypertension

Title: Beta-blockers to prevent decompensation of cirrhosis: an emulation of the PREDESCI trial

Presenter: Elliot Tapper

Abstract n°1249

Category: Cirrhosis and its complications (1): Portal Hypertension

Title: Safety of direct oral anticoagulants (DOACs) in patients with advanced liver disease

Presenter: Georg Semmler

Abstract n°1278

Category: Cirrhosis and its complications (1): Portal Hypertension

Title: Does continuing anticoagulation increase the risk of bleeding during variceal band ligation in patients with portal hypertension? A meta-analysis and systematic review

Presenter: Darren Tan

Abstract n°1316

Category: Cirrhosis and its complications (1): Portal Hypertension

Title: Factor VIII/protein C ratio independently predicts liver-related events but does not reflect the hypercoagulable state in patients with advanced chronic liver disease

Presenter: Lorenz Balcar

Abstract n°1474

Category: Cirrhosis and its complications (1): Portal Hypertension

Title: A new strategy to screen varices needing treatment via risk ranked from 0 to 100% by VARS and VANT tests

Presenter: Paul Cales

Abstract n°1544

Category: Cirrhosis and its complications (1): Portal Hypertension

Title: Anticoagulation improves overall survival through portal vein recanalization in patients with cirrhosis and portal vein thrombosis: Individual patient data meta-analysis (IMPORTAL study)

Presenter: Antonio Guerrero

Abstract n°1613

Category: Cirrhosis and its complications (1): Portal Hypertension

Title: Clinical significance of substantially elevated von Willebrand factor antigen levels in patients with advanced chronic liver disease

Presenter: Katharina Pomej

Abstract n°1705

Category: Cirrhosis and its complications (1): Portal Hypertension

Title: Application of a machine learning model to improve performance of endoscopic classification for prediction bleeding in patients with compensated cirrhosis with esophageal varices

Presenter: Samagra Agarwal

Abstract n°1987

Category: Cirrhosis and its complications (1): Portal Hypertension

Title: Carvedilol improves risk of decompensation and survival in compensated cirrhosis. A competing-risk meta-analysis of individual patient data

Presenter: Candid VILLANUEVA

Abstract n°2136

Category: Cirrhosis and its complications (1): Portal Hypertension

Title: Clinical decompensation and outcomes in patients with biopsy proven cirrhosis and a hepatic venous pressure gradient ≤ 10 mm Hg

Presenter: Ankur Jindal

Abstract n°2162

Category: Cirrhosis and its complications (1): Portal Hypertension

Title: Value of Hitachi Shear Wave Elastography (SWE) to rule-in and rule-out the presence of esophageal varices in patients with compensated advanced liver disease

Presenter: Simona Bota

Abstract n°2238

Category: Cirrhosis and its complications (1): Portal Hypertension

Title: Influence of Shunt occlusion on Organ Functions in Hyperammonemic patients with Cirrhosis having Porto-systemic Shunt: a randomized controlled trial

Presenter: Amar Mukund

Abstract n°2294

Category: Cirrhosis and its complications (1): Portal Hypertension

Title: Prognostic impact of Hepatic venous pressure gradient cut-off of 10mm Hg to predict clinical decompensations in patients with compensated cirrhosis with liver stiffness above 25 kilopascals

Presenter: Ankur Jindal

Abstract n°2298

Category: Cirrhosis and its complications (1): Portal Hypertension

Title: Prediction of cardiac outcomes post-transjugular intrahepatic portosystemic shunt placement using cirrhotic cardiomyopathy criteria

Presenter: Claire Harrington

Abstract n°2305

Category: Cirrhosis and its complications (1): Portal Hypertension

Title: Rifaximin for Prophylaxis of Post-TIPPS Hepatic Encephalopathy- A Meta Analysis

Presenter: Aminah Abdul Razzack

Abstract n°2381

Category: Cirrhosis and its complications (1): Portal Hypertension

Title: The modifications of adipose tissue and muscle mass are associated to the reduction of hepatic encephalopathy after TIPS

Presenter: Stefania Gioia

Abstract n°2403

Category: Cirrhosis and its complications (1): Portal Hypertension

Title: A single assessment of acute hemodynamic response to intravenous propranolol predicts hepatic decompensation in cirrhotic patients with portal hypertension

Presenter: Benedikt S Hofer

Abstract n°552

Category: Cirrhosis and its complications (2): ACLF and Critical illness

Title: The landscape of mitochondrial dysfunction in circulating leukocytes of patients with acute-on-chronic liver failure is characterized by altered mitochondrial metabolism and structure

Presenter: Ingrid Wei Zhang

Abstract n°638

Category: Cirrhosis and its complications (2): ACLF and Critical illness

Title: PD-L1 expression of monocytes relates to severity, infection and mortality in acute-on-chronic liver failure

Presenter: Evangelos Triantafyllou

Abstract n°675

Category: Cirrhosis and its complications (2): ACLF and Critical illness

Title: Increased incidence of respiratory failure with terlipressin use in patients with hepatorenal syndrome type 1 and severe acute-on-chronic liver failure

Presenter: Florence Wong

Abstract n°845

Category: Cirrhosis and its complications (2): ACLF and Critical illness

Title: Treatment of hepatorenal syndrome type 1 with terlipressin reduces need for renal replacement therapy post-liver transplantation

Presenter: Juan Carlos Q. Velez

Abstract n°968

Category: Cirrhosis and its complications (2): ACLF and Critical illness

Title: Terlipressin improves renal replacement therapy-free survival in hepatorenal syndrome type 1

Presenter: Juan Carlos Q. Velez

Abstract n°984

Category: Cirrhosis and its complications (2): ACLF and Critical illness

Title: Hepatopulmonary Syndrome is related with the Development of Acute-on Chronic Liver Failure and Poor prognosis in Cirrhotic patients.

Presenter: Han Seul ki

Abstract n°1161

Category: Cirrhosis and its complications (2): ACLF and Critical illness

Title: Impact of INFECTIONS on the post-operative survival of ACUTE-ON-CHRONIC LIVER FAILURE patients undergoing LIVER TRANSPLANTATION

Presenter: Elina Lam

Abstract n°1387

Category: Cirrhosis and its complications (2): ACLF and Critical illness

Title: Plasma Soluble CD14 predicted development of hospital acquired infection in decompensated cirrhosis patients from the ATTIRE trial

Presenter: Louise China

Abstract n°1501

Category: Cirrhosis and its complications (2): ACLF and Critical illness

Title: Ascitic fluid lactic acid is an accurate predictor of mortality in patients with spontaneous bacterial peritonitis

Presenter: Ilianna Mani

Abstract n°1585

Category: Cirrhosis and its complications (2): ACLF and Critical illness

Title: Potential mechanisms underlying the protective effect of long-term albumin infusion in cirrhosis

Presenter: Qianwen Zhao

Abstract n°1997

Category: Cirrhosis and its complications (2): ACLF and Critical illness

Title: A multi-centre, randomized controlled study, to evaluate the safety and performance of the DIALIVE Liver Dialysis Device in patients with Acute on Chronic Liver Failure (ACLF) versus standard of care (SOC).

Presenter: Banwari Agarwal

Abstract n°2058

Category: Cirrhosis and its complications (2): ACLF and Critical illness

Title: Stem Cell Transplantation in patients with cirrhosis and acute-on-chronic liver failure: A randomized, double-blind placebo control trial.

Presenter: Enric Reverter

Abstract n°2060

Category: Cirrhosis and its complications (2): ACLF and Critical illness

Title: Pathophysiological basis of resolution of Acute-on-Chronic Liver Failure (ACLF) induced by the novel liver dialysis device, DIALIVE

Presenter: Rafael Banares Canizares

Abstract n°2142

Category: Cirrhosis and its complications (2): ACLF and Critical illness

Title: COMPARISON OF 20% ALBUMIN VERSUS CRYSTALLOID PLASMA-LYTE FOR FLUID RESUSCITATION IN CIRRHOTICS WITH SEPSIS INDUCED HYPOTENSION AN OPEN LABEL RANDOMIZED CONTROLLED TRIAL

Presenter: Rakhi Maiwall

Abstract n°2147

Category: Cirrhosis and its complications (2): ACLF and Critical illness

Title: Intestinal epithelial cell signalling and cell death in Cirrhosis and Acute-on-Chronic Liver Failure

Presenter: Stijn Aaron den Daas

Abstract n°2313

Category: Cirrhosis and its complications (2): ACLF and Critical illness

Title: IL-1Ra, IL-18 and TREM-1 circulating factors and CD+ve HLADR-low TIM3+ve suppressive monocytes predict development of sepsis within 3 days in patients with acute on chronic failure

Presenter: Pushpa Yadav

Abstract n°2358

Category: Cirrhosis and its complications (2): ACLF and Critical illness

Title: Modification of the CLIF-C ACLF score improves the predictive accuracy by adjusting for risk factors mechanical ventilation and pulmonary failure

Presenter: Martin Schulz

Abstract n°31

Category: Cirrhosis and its complications (3): Other clinical complications except ACLF and critical illness

Title: Branched chain amino acids do not improve muscle mass in patients of cirrhosis with sarcopenia: A double blind randomized placebo controlled trial

Presenter: Srikant Mohta

Abstract n°187

Category: Cirrhosis and its complications (3): Other clinical complications except ACLF and critical illness

Title: Non-malignant portal vein thrombi in patients with cirrhosis consist of intimal fibrosis with or without a fibrin-rich thrombus

Presenter: Ellen Driever

Abstract n°342

Category: Cirrhosis and its complications (3): Other clinical complications except ACLF and critical illness

Title: Improved survival and reduced risk of hospital admissions after 12-weeks of resistance training in patients with cirrhosis - a three year follow-up from randomization

Presenter: Luise Aamann

Abstract n°485

Category: Cirrhosis and its complications (3): Other clinical complications except ACLF and critical illness

Title: Baveno-VI criteria to predict variceal bleeding and liver decompensation in compensated cirrhosis patients

Presenter: FRANCIS TEH

Abstract n°513

Category: Cirrhosis and its complications (3): Other clinical complications except ACLF and critical illness

Title: Algorithm combining fat-free muscle index and total spontaneous portosystemic shunt area indentifies high-risk cirrhotic patients

Presenter: Michael Praktijn

Abstract n°714

Category: Cirrhosis and its complications (3): Other clinical complications except ACLF and critical illness

Title: prognostic impacts of the change in muscle mass on patients with cirrhosis

Presenter: Tae Hyung Kim

Abstract n°835

Category: Cirrhosis and its complications (3): Other clinical complications except ACLF and critical illness

Title: Safety of 11,043 paracentesis in patients with liver cirrhosis with and without anticoagulant treatment. Large, retrospective, unicentric study.

Presenter: Jordi Vives Moreno

Abstract n°864

Category: Cirrhosis and its complications (3): Other clinical complications except ACLF and critical illness

Title: Further analysis of simvastatin safety trial in patients with decompensated cirrhosis provides promising information about improving liver function and reducing cirrhosis severity

Presenter: Alberto Muñoz

Abstract n°918

Category: Cirrhosis and its complications (3): Other clinical complications except ACLF and critical illness

Title: Low myocardial mechano-energetic efficiency is an independent predictor of prognosis in patients with advanced chronic liver disease

Presenter: Maurizio Cesari

Abstract n°925

Category: Cirrhosis and its complications (3): Other clinical complications except ACLF and critical illness

Title: Covered transjugular intrahepatic portosystemic shunt implantation improves renal function in patients with cirrhosis and ascites

Presenter: Theresa Bucsics

Abstract n°932

Category: Cirrhosis and its complications (3): Other clinical complications except ACLF and critical illness

Title: Prevalence and prognostic value of cirrhotic cardiomyopathy as defined according with the new proposed classification

Presenter: Maurizio Cesari

Abstract n°974

Category: Cirrhosis and its complications (3): Other clinical complications except ACLF and critical illness

Title: Evaluation of cardiac function in cirrhosis across different prognostic stages; A focus on plasma biomarkers of fibrosis

Presenter: Jolanta Zuwała-Jagiełło

Abstract n°1045

Category: Cirrhosis and its complications (3): Other clinical complications except ACLF and critical illness

Title: A Double Blind, Randomised, Placebo-Controlled Study To Assess Safety and Tolerability of Oral Enterosorbent Yaq-001 In Cirrhotic Patients (CARBALIVE Consortium)

Presenter: Jane Macnaughtan

Abstract n°1102

Category: Cirrhosis and its complications (3): Other clinical complications except ACLF and critical illness

Title: Epidemiology of spontaneous bacterial peritonitis and bacterascites in patients with cirrhosis in Queensland, Australia from 2008-2017

Presenter: Amy Johnson

Abstract n°1165

Category: Cirrhosis and its complications (3): Other clinical complications except ACLF and critical illness

Title: Cirrhocare - a pilot study of digital home-monitoring of advanced cirrhosis to determine feasibility and utility to diagnose new decompensation events.

Presenter: Konstantin Kazankov

Abstract n°1266

Category: Cirrhosis and its complications (3): Other clinical complications except ACLF and critical illness

Title: Changes in gas-exchange abnormalities over time in patients with moderate to severe hepatopulmonary syndrome

Presenter: Xun Zhao

Abstract n°1462

Category: Cirrhosis and its complications (3): Other clinical complications except ACLF and critical illness

Title: Efficacy and safety of albumin infusion for treatment and prevention of hepatic encephalopathy: a systematic review and meta-analysis

Presenter: FRANCIS TEH

Abstract n°1471

Category: Cirrhosis and its complications (3): Other clinical complications except ACLF and critical illness

Title: Myostatin is associated with sarcopenia and in combination with creatinine phosphokinase or albumin may be used as a screening tool of sarcopenia in liver cirrhosis

Presenter: Theodoros Alexopoulos

Abstract n°1549

Category: Cirrhosis and its complications (3): Other clinical complications except ACLF and critical illness

Title: Circulating microRNAs profiling in acute decompensation of liver cirrhosis

Presenter: Yasmina Chouik

Abstract n°1670

Category: Cirrhosis and its complications (3): Other clinical complications except ACLF and critical illness

Title: Use of rifaximin is not associated with infections by multi-drug resistant bacteria, but with occurrence of rifampicin-resistance in coagulase-negative staphylococci

Presenter: Lina Schulte

Abstract n°1701

Category: Cirrhosis and its complications (3): Other clinical complications except ACLF and critical illness

Title: Low incidence of SARS-CoV-2 infection in a prospective cohort of patients with liver cirrhosis and hepatocellular carcinoma treated at a German tertiary center during the 2020 pandemic

Presenter: Lilith Kuballa

Abstract n°1712

Category: Cirrhosis and its complications (3): Other clinical complications except ACLF and critical illness

Title: Baseline liver volume is a major prognostic factor in acute decompensation of alcohol-associated cirrhosis: results from the prospective multicentre PROLIV study

Presenter: José Ursic-Bedoya

Abstract n°1730

Category: Cirrhosis and its complications (3): Other clinical complications except ACLF and critical illness

Title: Cirrhotic patients without prior antibiotic exposure may be eligible to lower first-line antibiotic strategies for nosocomial infections: results from a local antibiotic resistance study

Presenter: Fanny Lebossé

Abstract n°1766

Category: Cirrhosis and its complications (3): Other clinical complications except ACLF and critical illness

Title: High risk medication-related problems are associated with lower quality of life in decompensated cirrhosis

Presenter: Kelly Hayward

Abstract n°1767

Category: Cirrhosis and its complications (3): Other clinical complications except ACLF and critical illness

Title: The prevalence of sarcopenia and myosteatosis in cirrhotic patients: preliminary results from an Italian multicenter study (EptoSarco Group)

Presenter: Simone Di Cola

Abstract n°1864

Category: Cirrhosis and its complications (3): Other clinical complications except ACLF and critical illness

Title: Sex is a major effect modifier on the association between body composition and mortality in patients with cirrhosis assessed for liver transplantation

Presenter: Amine Benmassaoud

Abstract n°1930

Category: Cirrhosis and its complications (3): Other clinical complications except ACLF and critical illness

Title: Albumin dysfunction correlates with disease markers in patients with decompensated cirrhosis

Presenter: Raquel Horrillo

Abstract n°1998

Category: Cirrhosis and its complications (3): Other clinical complications except ACLF and critical illness

Title: A study evaluating outcomes of cirrhotic patients managed virtually in a specialist liver cirrhosis service due to the COVID crisis.

Presenter: Alex Cole

Abstract n°2194

Category: Cirrhosis and its complications (3): Other clinical complications except ACLF and critical illness

Title: Multidisciplinary assessment of neurocognitive impairment in a prospective cohort of patients with chronic liver disease: should we only think of hepatic encephalopathy?

Presenter: Sultanik Philippe

Abstract n°2273

Category: Cirrhosis and its complications (3): Other clinical complications except ACLF and critical illness

Title: The impact of age in clinical outcomes in cirrhotic outpatients

Presenter: Marta Tonon

Abstract n°134

Category: Cirrhosis and its complications (4): Experimental and pathophysiology

Title: Genetic variation in the mitochondrial glycerol-3-phosphate acyltransferase is associated with liver injury

Presenter: Aaron Hakim

Abstract n°624

Category: Cirrhosis and its complications (4): Experimental and pathophysiology

Title: Transcriptomic profiling of liver sinusoidal endothelial cells during cirrhosis progression reveals stage-specific secretory signature

Presenter: Jordi Gracia-Sancho

Abstract n°698

Category: Cirrhosis and its complications (4): Experimental and pathophysiology

Title: Characterizing sensory thresholds and autonomic dysfunction in cirrhotic patients with minimal hepatic encephalopathy

Presenter: Dalia Rega

Abstract n°709

Category: Cirrhosis and its complications (4): Experimental and pathophysiology

Title: Multi-omic analysis unveils biological pathways in peripheral immune system associated to minimal hepatic encephalopathy appearance in cirrhotic patients

Presenter: Carmina Montoliu

Abstract n°994

Category: Cirrhosis and its complications (4): Experimental and pathophysiology

Title: Hepatic fat loss in cirrhosis: Evaluation of malnutrition using MRI proton density fat fraction (MRI-PDFF)

Presenter: ATSUSHI NAKAMURA

Abstract n°1051

Category: Cirrhosis and its complications (4): Experimental and pathophysiology

Title: Systemic and hepatic endothelial cell activation biomarkers expression are associated with inflammation and disease progression in patients with cirrhosis

Presenter: Jelte Schaapman

Abstract n°1222

Category: Cirrhosis and its complications (4): Experimental and pathophysiology

Title: PNPLA3-associated cirrhosis: HSD17B13 and MBOAT7 variants as modulators of chronic liver injury.

Presenter: Marcin Krawczyk

Abstract n°1491

Category: Cirrhosis and its complications (4): Experimental and pathophysiology

Title: Hepatocellular carcinoma chemoprevention by inhibition of the angiotensin converting enzyme and EGFR transactivation

Presenter: Emilie Crouchet

Abstract n°1643

Category: Cirrhosis and its complications (4): Experimental and pathophysiology

Title: Nutritional supplementation with B-Hydroxy-B-methylbutyrate (HMB) in malnourished cirrhotic patients

Presenter: Silvia Espina

Abstract n°1684

Category: Cirrhosis and its complications (4): Experimental and pathophysiology

Title: Low-grade hyperammonemia induces severe neuronal mitochondrial dysfunction in cellular and animal models of hepatic encephalopathy

Presenter: Annarein Kerbert

Abstract n°1761

Category: Cirrhosis and its complications (4): Experimental and pathophysiology

Title: SLEEP STUDY WITH ACTIGRAPHY IN PATIENTS AFFECTED BY CIRRHOSIS WITH AND WITHOUT MINIMAL HEPATIC ENCEPHALOPATHY

Presenter: Cristina Ipiens

Abstract n°1787

Category: Cirrhosis and its complications (4): Experimental and pathophysiology

Title: Markers of neutrophil extracellular traps are elevated in patients with Child-Pugh B and C liver cirrhosis or large hepatocellular carcinomas

Presenter: Robin Zenlander

Abstract n°2098

Category: Cirrhosis and its complications (4): Experimental and pathophysiology

Title: GLAST redistributes, clusters and forms homomultimers at the plasma membrane

Presenter: Joana Patrícia Ventura Pereira

Abstract n°2213

Category: Cirrhosis and its complications (4): Experimental and pathophysiology

Title: Fingolimod Represents a Novel Therapy in Experimental Model of Hepatopulmonary Syndrome

Presenter: Sukriti Sukriti

Abstract n°2279

Category: Cirrhosis and its complications (4): Experimental and pathophysiology

Title: Obese-induced brain sphingolipid dysregulation in bile-duct ligated rats accelerates and exacerbates hepatic encephalopathy

Presenter: Rafael Ochoa-Sanchez

Abstract n°2382

Category: Cirrhosis and its complications (4): Experimental and pathophysiology

Title: Role of sex on the development of sarcopenia and ammonia metabolism in bile-duct ligated rats

Presenter: Mariana M. Oliveira

Abstract n°2420

Category: Cirrhosis and its complications (4): Experimental and pathophysiology

Title: Impact of a loss-of-function variant in HSD17B13 on hepatic decompensation and mortality in cirrhotic patients

Presenter: Antonio Gil-Gomez

Abstract n°89

Category: Fibrosis

Title: Survivin inhibition ameliorates liver fibrosis via inducing senescence in hepatic stellate cells

Presenter: Sachin Sharma

Abstract n°223

Category: Fibrosis

Title: Precision-cut liver slices as a dynamic tool to model liver fibrosis in vitro

Presenter: Liza Dewyse

Abstract n°410

Category: Fibrosis

Title: The inhibition of the YAP-1/CTGF pathway improves chronic biliary fibrosis in the Abcb4^{-/-} model by modulation of hepatic stellate cell physiology

Presenter: Liangtao Ye

Abstract n°477

Category: Fibrosis

Title: hepatic Ipi/gpr55 system regulates the development of non-alcoholic steatosis and steatohepatitis

Presenter: Uxía Fernández

Abstract n°479

Category: Fibrosis

Title: Inhibition of hepatic p63 reduces the fibrosis in NASH

Presenter: Marcos Fernandez Fondevila

Abstract n°567

Category: Fibrosis

Title: B-cell-mediated fibrogenesis in non-alcoholic steatohepatitis

Presenter: Anja MONCSEK

Abstract n°663

Category: Fibrosis

Title: Pharmacokinetics, safety, and tolerability of multiple-dose CC-90001, a c-Jun N-terminal kinase (JNK) inhibitor, in healthy Japanese and non-Japanese adults

Presenter: Allison Gaudy

Abstract n°692

Category: Fibrosis

Title: HBV-infection induces collagen VI expression by hepatocytes promoting stellate cell-activation and liver fibrosis

Presenter: Alessia Virzi

Abstract n°733

Category: Fibrosis

Title: Pharmacokinetics, safety, and tolerability of CC-90001, a c-Jun N-terminal kinase (JNK) inhibitor, in participants with hepatic impairment

Presenter: Kofi A Mensah

Abstract n°793

Category: Fibrosis

Title: Endothelial GATA4 deficiency causes perisinusoidal liver fibrosis by impaired angiocrine signaling

Presenter: Manuel Winkler

Abstract n°874

Category: Fibrosis

Title: A fully agonistic anti-MET antibody protects hepatocytes against acute and chronic injury, promotes fibrosis regression and restores liver function in cirrhotic mice

Presenter: Virginia Morello

Abstract n°888

Category: Fibrosis

Title: CtsD deficient macrophages display altered proteolytic profile and dysregulated collagen recycling, resulting in increased liver fibrosis

Presenter: Paloma Ruiz-Blázquez

Abstract n°938

Category: Fibrosis

Title: Therapeutic targeting of integrin alpha v beta 1 in liver fibrosis

Presenter: Emma Shepherd

Abstract n°1069

Category: Fibrosis

Title: The AST/ALT ratio: a second line component of the hepatic fibrosis screening by FIB-4 calculated automatically in 131,861 subjects.

Presenter: Denis Ouzan

Abstract n°1125

Category: Fibrosis

Title: Using the Enhanced Liver Fibrosis test in Primary Care: A practical pathway to prioritise patients with fibrosis in Fatty Liver Disease

Presenter: Alexander Hinkson

Abstract n°1441

Category: Fibrosis

Title: Characterization and study of hepatic stellate cells in a 3D bioengineered model of fibrosis

Presenter: Sara Campinoti

Abstract n°1478

Category: Fibrosis

Title: HSC-targeted plasmonic hyperthermia treatment reduces liver fibrosis in mice

Presenter: Jordi Ribera

Abstract n°1505

Category: Fibrosis

Title: Fibrosis Biomarkers CA15-3 and Thrombospondin-2 are Associated with Higher Hepatic Collagen Content in Non-alcoholic Steatohepatitis (NASH)-related Fibrosis

Presenter: Sean Felix

Abstract n°1575

Category: Fibrosis

Title: Fibrosis response assessed by enhanced liver fibrosis and FibroScan liver stiffness measurement in patients with non-alcoholic steatohepatitis treated with subcutaneous semaglutide

Presenter: Quentin Anstee

Abstract n°1579

Category: Fibrosis

Title: Chinese traditional medicine Yiqi Huoxue recipe attenuates hepatic fibrosis via the YAP/TAZ signaling

Presenter: Wen Zhao

Abstract n°1580

Category: Fibrosis

Title: Prospective screening of significant liver fibrosis in a large cohort of 131,861 French subjects using, since October 2020, automatic calculation of FIB-4 in routine blood tests.

Presenter: Denis Ouzan

Abstract n°1582

Category: Fibrosis

Title: Inter-system reproducibility of liver stiffness measurement with two different two-dimensional shear wave elastography techniques using transient elastography as the reference method

Presenter: Victor Baldea

Abstract n°1589

Category: Fibrosis

Title: Non-alcoholic steatohepatitis-related costs changes in the context of fibrosis progression status in European patients

Presenter: Leonardo Ruiz Casas

Abstract n°1609

Category: Fibrosis

Title: The impact of liver fibrosis progression on the Health-related quality of life of patients with non-alcoholic steatohepatitis in clinical practice in Europe

Presenter: Leonardo Ruiz Casas

Abstract n°1831

Category: Fibrosis

Title: Combinations of an acetyl CoA carboxylase inhibitor, FXR agonist and GLP-1R agonist inhibits fibrosis progression in the rat choline-deficient, L-amino acid defined, high-fat diet model of advanced fibrosis

Presenter: Archana Vijayakumar

Abstract n°1857

Category: Fibrosis

Title: AI digital pathology using qFibrosis reveals heterogeneity of fibrosis regression in hepatitis B and C patients with SVR

Presenter: Feng Liu

Abstract n°1935

Category: Fibrosis

Title: The hepatoprotective role of the antiretroviral drug Rilpivirine is associated with altered autophagy in in vitro and in vivo models of liver fibrosis

Presenter: Federico Lucantoni

Abstract n°2069

Category: Fibrosis

Title: Claudin-1 is a target for treatment of advanced liver fibrosis and cancer prevention

Presenter: Natascha Roehlen

Abstract n°2113

Category: Fibrosis

Title: Proteomic profiling of hepatic stellate cell differentiation from induced pluripotent stem cells: new tools to understand liver development and fibrosis

Presenter: Raquel A. Martinez Garcia de la Torre

Abstract n°2415

Category: Fibrosis

Title: An integrated approach on immune cell subtype characterization reveals common inflammatory pathways in non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC)

Presenter: Milessa Silva Afonso

Abstract n°119

Category: Gut microbiota and liver disease

Title: Virulence factors in gut metagenomics worsen with disease progression and predict outcomes in cirrhosis

Presenter: Jasmohan S Bajaj

Abstract n°418

Category: Gut microbiota and liver disease

Title: Rifaximin and Fecal Microbiota Transplant beneficially modulate gut metagenomic virulence factors in cirrhosis: Analysis of two trials

Presenter: Jasmohan S Bajaj

Abstract n°799

Category: Gut microbiota and liver disease

Title: Response failure to ursodeoxycholic acid treatment in primary biliary cholangitis is associated with a distinct stool and urine secondary bile acid profile

Presenter: Laura Martinez-Gili

Abstract n°1167

Category: Gut microbiota and liver disease

Title: Faecal microbiota transplantation improves intestinal barrier function and modulates mucosal IL-17 immunity in patients with advanced cirrhosis

Presenter: Lindsey A Edwards

Abstract n°1558

Category: Gut microbiota and liver disease

Title: Hepatobiliary Phenotype of Individuals with Chronic Intestinal Disorders - The Gut-Liver Axis in UKBiobank

Presenter: Jessica Voss

Abstract n°1763

Category: Gut microbiota and liver disease

Title: Rifaximin suppresses gut-derived systemic inflammation and promotes a gut microenvironment with reduced mucin degradation conducive to gut barrier repair in patients with cirrhosis and hepatic encephalopathy

Presenter: Debbie L. Shawcross

Abstract n°1979

Category: Gut microbiota and liver disease

Title: Paneth cells regulate lymphangiogenesis in normal physiology and experimental portal hypertension

Presenter: Oriol Juanola

Abstract n°2010

Category: Gut microbiota and liver disease

Title: Ethanol induced alterations in intestinal microbiota correlate with decreased intestinal nuclear receptor (PXR) pathway related proteins

Presenter: Sudrishti Chaudhary

Abstract n°2044

Category: Gut microbiota and liver disease

Title: In-depth shotgun metagenomic analysis of the gut microbiome identifies striking variations in microbial community structure based on severity and stage of cirrhosis

Presenter: Bethlehem Arefaine

Abstract n°2363

Category: Gut microbiota and liver disease

Title: Role of farensoid-X receptor agonist in ameliorating NASH-disrupted intestinal permeability: Potential impact of autophagy on tight junctions

Presenter: Rasha Tawfiq

Abstract n°301

Category: Imaging and drug targeting

Title: Artificial Intelligence in medical imaging of the liver - a convolutional neural network solution for Computed Tomography exam phases recognition

Presenter: João Martins Cortez Filho

Abstract n°629

Category: Imaging and drug targeting

Title: Multiparametric MRI as non-invasive tool to assess disease activity in autoimmune hepatitis

Presenter: Johannes Hartl

Abstract n°738

Category: Imaging and drug targeting

Title: Theranostic nanodots with ggregation-induced emmission and nuclear magnetic resonance imaging characteristics for targeted and image-guided siRNA therapy of hepatocellular carcinoma

Presenter: yuchen hou

Abstract n°985

Category: Imaging and drug targeting

Title: The liver fibroinflammatory marker cT1 is reduced with aldafermin therapy in a randomized, double-blind, placebo-controlled, multicenter study in patients with nonalcoholic steatohepatitis

Presenter: Angelo Paredes

Abstract n°1023

Category: Imaging and drug targeting

Title: Intravital dynamic and correlative imaging reveals the mechanism of canalicular bile flux

Presenter: Nachiket Vartak

Abstract n°2076

Category: Imaging and drug targeting

Title: Pharmacological MKK4 Inhibition unlocks Liver Regeneration and attenuates Liver Damage in rodent and non-rodent Liver Disease Models.

Presenter: Lars Zender

Abstract n°60

Category: Immune-mediated and cholestatic disease: Clinical aspects

Title: Quantification of polyreactive immunoglobulin G facilitates diagnosis of autoimmune hepatitis

Presenter: Bastian Engel

Abstract n°127

Category: Immune-mediated and cholestatic disease: Clinical aspects

Title: Quality of life is impaired in both physical and mental health domains, in patients with Autoimmune Hepatitis: A systematic review and meta-analysis

Presenter: Selena Dixon

Abstract n°210

Category: Immune-mediated and cholestatic disease: Clinical aspects

Title: A Dose-Finding, Positive Proof of Concept study of HTD1801 in Patients with Primary Sclerosing Cholangitis

Presenter: Kris Kowdley

Abstract n°254

Category: Immune-mediated and cholestatic disease: Clinical aspects

Title: Effectiveness of obeticholic acid in patients with primary biliary cholangitis stratified by biochemical marker status in the real-world setting in the United States

Presenter: Amy Law

Abstract n°344

Category: Immune-mediated and cholestatic disease: Clinical aspects

Title: Immunohistochemical staining of cholangioscopy-directed biopsies of cholangiocarcinoma in Primary Sclerosing Cholangitis

Presenter: Stephanie Yan

Abstract n°376

Category: Immune-mediated and cholestatic disease: Clinical aspects

Title: Cluster analysis reveals the prognostic role of serum albumin within the normal range in patients with primary biliary cholangitis

Presenter: Alessio Gerussi

Abstract n°706

Category: Immune-mediated and cholestatic disease: Clinical aspects

Title: Blue-collar work increases the risk of developing IgG4-RD of the biliary tract and pancreas

Presenter: Lowiek Hubers

Abstract n°770

Category: Immune-mediated and cholestatic disease: Clinical aspects

Title: Real-world evaluation of second line therapy in Primary Biliary Cholangitis: A multicentre nationwide study

Presenter: Nadir Abbas

Abstract n°860

Category: Immune-mediated and cholestatic disease: Clinical aspects

Title: Hepatolithiasis is a frequent and prognostic finding in patients with primary sclerosing cholangitis

Presenter: Bellal Jubran

Abstract n°872

Category: Immune-mediated and cholestatic disease: Clinical aspects

Title: Circulating B-cell activating factor of the tumour necrosis family (BAFF) and interleukin 21 levels predict treatment response in patients with autoimmune hepatitis

Presenter: Maaike Biewenga

Abstract n°894

Category: Immune-mediated and cholestatic disease: Clinical aspects

Title: Liver stiffness assessed by Fibroscan is a surrogate endpoint of outcomes of UDCA-treated patients with PBC: an international follow-up study

Presenter: Christophe Corpechot

Abstract n°1017

Category: Immune-mediated and cholestatic disease: Clinical aspects

Title: Non-invasive scores of hepatic fibrosis in autoimmune hepatitis

Presenter: Marco Ferronato

Abstract n°1074

Category: Immune-mediated and cholestatic disease: Clinical aspects

Title: The FGF19 analogue aldafermin enriches the lactate-consuming, bile acid-sensitive commensal microbe Veillonella in patients with primary sclerosing cholangitis

Presenter: Lei Ling

Abstract n°1088

Category: Immune-mediated and cholestatic disease: Clinical aspects

Title: Hepatobiliary malignancy surveillance strategies in primary sclerosing cholangitis associate with reduced mortality

Presenter: Annika M Bergquist

Abstract n°1213

Category: Immune-mediated and cholestatic disease: Clinical aspects

Title: Multicentre international evaluation of autoimmune hepatitis and liver transplantation: disease recurrence is associated with recipient features, type of immunosuppression and impaired outcomes

Presenter: Aldo J Montano-Loza

Abstract n°1294

Category: Immune-mediated and cholestatic disease: Clinical aspects

Title: Implementation of a national registry for patients with primary biliary cholangitis (PBC): The German PBC cohort

Presenter: Johannes Wiegand

Abstract n°1418

Category: Immune-mediated and cholestatic disease: Clinical aspects

Title: Risk of primary biliary cholangitis in first degree relatives: a prospective cohort study

Presenter: Johannes Hartl

Abstract n°1428

Category: Immune-mediated and cholestatic disease: Clinical aspects

Title: The measurement properties of the Dutch PBC-40: a validation study

Presenter: Rozanne de Veer

Abstract n°1484

Category: Immune-mediated and cholestatic disease: Clinical aspects

Title: Prevalence of immunological tolerance among type 1 autoimmune hepatitis patients on long-term remission

Presenter: Maria Carlota Londoño

Abstract n°1486

Category: Immune-mediated and cholestatic disease: Clinical aspects

Title: Patient perspective on treatment and prognosis in Primary Biliary Cholangitis: a descriptive study

Presenter: Maria van Hooff

Abstract n°1512

Category: Immune-mediated and cholestatic disease: Clinical aspects

Title: Multimarker analysis combining markers of fibrosis and inflammation in primary sclerosing cholangitis

Presenter: Guri Fossdal

Abstract n°1574

Category: Immune-mediated and cholestatic disease: Clinical aspects

Title: MARC1 p.A165T polymorphism is associated with decreased liver injury and enhanced antioxidant activity in serum in patients with AIH

Presenter: Maciej K. Janik

Abstract n°1586

Category: Immune-mediated and cholestatic disease: Clinical aspects

Title: Patterns of biochemical response during long-term UDCA treatment in patients with primary biliary cholangitis: association with liver transplant-free survival

Presenter: Surain Roberts

Abstract n°1664

Category: Immune-mediated and cholestatic disease: Clinical aspects

Title: Incidence of hepatic outcomes in patients with cirrhosis due to primary biliary cholangitis: A population-based epidemiology study

Presenter: Lina Titievsky

Abstract n°1728

Category: Immune-mediated and cholestatic disease: Clinical aspects

Title: Frequency, clinical features and outcomes of COVID-19 in patients with IgG4-related hepatopancreato-biliary disease: a collaborative European multi-centre study

Presenter: Emma Culver

Abstract n°1748

Category: Immune-mediated and cholestatic disease: Clinical aspects

Title: Improvement in itch correlates with improved sleep in GLIMMER, a Phase 2b trial of linerixibat for the treatment of cholestatic pruritus in primary biliary cholangitis

Presenter: David Jones

Abstract n°1755

Category: Immune-mediated and cholestatic disease: Clinical aspects

Title: Younger age is associated with lower self-reported quality of life among patients with autoimmune disease during Canada's response to the COVID-19 pandemic

Presenter: Christina Plagiannakos

Abstract n°1790

Category: Immune-mediated and cholestatic disease: Clinical aspects

Title: National audit of diagnosis, management and surveillance in primary sclerosis cholangitis (PSC) in the United Kingdom.

Presenter: Evangelia Fatourou

Abstract n°1799

Category: Immune-mediated and cholestatic disease: Clinical aspects

Title: Among cancer patients, autoimmune hepatitis with cirrhosis increases mortality

Presenter: Morten Daniel Jensen

Abstract n°2015

Category: Immune-mediated and cholestatic disease: Clinical aspects

Title: Immunological Background Pinpoints Patients at High Risk of Immune-related Hepatitis Recurrence during Check-points Inhibitors Rechallenge

Presenter: Ana Barreira

Abstract n°2096

Category: Immune-mediated and cholestatic disease: Clinical aspects

Title: Surrogate markers for bile duct disease progression assessed by sequential ERCP examinations in primary sclerosing cholangitis

Presenter: Martti Färkkilä

Abstract n°2230

Category: Immune-mediated and cholestatic disease: Clinical aspects

Title: Safety and efficacy of the JAK-inhibitor tofacitinib in patients with primary sclerosis cholangitis: a multicentre, retrospective study

Presenter: Ida Schregel

Abstract n°2259

Category: Immune-mediated and cholestatic disease: Clinical aspects

Title: Intravenous ketamine and progressive cholangiopathy in covid-19 patients

Presenter: Kilian Bock

Abstract n°2280

Category: Immune-mediated and cholestatic disease: Clinical aspects

Title: Identifying the early predictors of non-response to steroids in patients with flare of autoimmune hepatitis causing acute on chronic liver failure

Presenter: Sanchit Sharma

Abstract n°2327

Category: Immune-mediated and cholestatic disease: Clinical aspects

Title: Hepatic safety assessment of obeticholic acid (OCA) in primary biliary cholangitis (PBC): A post-hoc evaluation of a long term safety extension study with an external PBC cohort

Presenter: Gideon Hirschfield

Abstract n°855

Category: Immune-mediated and cholestatic: Experimental and pathophysiology

Title: Potential effect of a novel long-acting Glucagon/GIP/GLP-1 triple agonist, HM15211, in preclinical model of cholestatic liver disease

Presenter: Jung Kuk Kim

Abstract n°899

Category: Immune-mediated and cholestatic: Experimental and pathophysiology

Title: Deletion of Mcpip1 in Mcpip1fl/flAlbCre mice recapitulates the phenotype of human primary biliary cholangitis

Presenter: Jerzy Kotlinowski

Abstract n°903

Category: Immune-mediated and cholestatic: Experimental and pathophysiology

Title: cholangiopathy-related necroptotic cell death recapitulated in human cholangiocyte organoids for screening novel drug targets

Presenter: Shaojun Shi

Abstract n°1026

Category: Immune-mediated and cholestatic: Experimental and pathophysiology

Title: Serum nuclear magnetic resonance metabolomic signature can discriminate between immunoglobulin G4-related sclerosing cholangitis and primary sclerosing cholangitis

Presenter: Emmanuel Selvaraj

Abstract n°1311

Category: Immune-mediated and cholestatic: Experimental and pathophysiology

Title: The peri-ductular CCL24 rich niche promotes bile duct fibrosis related liver damage in primary sclerosing cholangitis

Presenter: Arnon Aharon

Abstract n°1364

Category: Immune-mediated and cholestatic: Experimental and pathophysiology

Title: Is it the scale (rather than the nature) of the inflammatory response in autoimmune hepatitis that determines treatment response?

Presenter: Jessica Dyson

Abstract n°1822

Category: Immune-mediated and cholestatic: Experimental and pathophysiology

Title: Cellular immune responses to human betaretrovirus in patients with primary biliary cholangitis

Presenter: Hiatem Abofayed

Abstract n°1847

Category: Immune-mediated and cholestatic: Experimental and pathophysiology

Title: A3907, a novel orally bioavailable inhibitor of the apical sodium-dependent bile acid transporter, improves liver injury in a mouse model of cholestatic liver disease

Presenter: Peter Akerblad

Abstract n°1946

Category: Immune-mediated and cholestatic: Experimental and pathophysiology

Title: CCR2+ monocytes induce hepatic accumulation and activation of tissue destructive CD8+ T cells in a murine model of checkpoint inhibitor-induced hepatitis

Presenter: Cathrin L.C. Gudd

Abstract n°2274

Category: Immune-mediated and cholestatic: Experimental and pathophysiology

Title: Farnesoid X Receptor agonists block macrophage derived IL1beta production, disrupt Th1/Th17 polarization of effector lymphocytes, and ameliorates disease progression in murine sclerosing cholangitis

Presenter: Astha Malik

Abstract n°2285

Category: Immune-mediated and cholestatic: Experimental and pathophysiology

Title: Vitamin B6 deficiency associates with liver transplantation-free survival in primary sclerosing cholangitis

Presenter: Peder Rustøen Braadland

Abstract n°2388

Category: Immune-mediated and cholestatic: Experimental and pathophysiology

Title: FXR Controls Effector Cytokine Production and Phenotype in Biliary Atresia

Presenter: Annika Yang vom Hofe

Abstract n°147

Category: Immunology

Title: Hepatitis B vaccine NON-RESPONDERS show higher frequencies of REGULATORY B CELLS, but lower levels of IL-10 expression compared to responders

Presenter: Laureen Pohl

Abstract n°216

Category: Immunology

Title: Liver resident Natural Killer cells are the dominant source of Fas ligand during chronic Hepatitis B virus mediated liver damage

Presenter: Adrian Kuiper

Abstract n°235

Category: Immunology

Title: Combined PD-1 blockade plus IL-15 treatment restores HBV-specific CD8 T cell reactivity in short-term nucleos(t)ide analogue treated eAg chronic hepatitis B

Presenter: Julia Peña Asensio

Abstract n°240

Category: Immunology

Title: Identification of a CD8 T cell population with a transcriptional profile consistent with non-specific hepatocyte killing in the inflamed human liver of chronic hepatitis B patients

Presenter: Shirin Nkongolo

Abstract n°262

Category: Immunology

Title: Blood-derived extracellular vesicles of patients with liver cirrhosis and acute-on-chronic liver failure display immunomodulatory functions

Presenter: Mona-May Langer

Abstract n°718

Category: Immunology

Title: Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy

Presenter: Sam Murray

Abstract n°846

Category: Immunology

Title: Chronic Hepatitis B inflammation gives rise to a novel macrophage population in the human liver

Presenter: Juan Diego Sanchez

Abstract n°896

Category: Immunology

Title: Stimulation of Mucosal-associated invariant T (MAIT) cells by human serum derived from peripheral and portal blood

Presenter: Martin Lett

Abstract n°1171

Category: Immunology

Title: Non-autonomous induction of endothelial RelA underpins immune-mediated surveillance of premalignant hepatocytes

Presenter: Kelvin Yin

Abstract n°1299

Category: Immunology

Title: Selective depletion of HBsAg-specific B cells in paediatric HBV infection

Presenter: Sabela Lens

Abstract n°1333

Category: Immunology

Title: Osteopontin expression identifies a subset of macrophages distinct from Kupffer Cells in the fatty liver

Presenter: Anneleen Remmerie

Abstract n°1460

Category: Immunology

Title: Harnessing liver-resident gamma delta T cells for immunotherapy of hepatocellular carcinoma

Presenter: Nekisa Zakeri

Abstract n°1472

Category: Immunology

Title: CD4 T cell tolerance induced by nanoparticle-mediated autoantigen delivery to liver sinusoidal endothelial cells depends on interferon-gamma

Presenter: Daria Krzikalla

Abstract n°1598

Category: Immunology

Title: Investigating the potential association of elevated plasma Leukotriene B4 and survival in females in the ATTIRE trial

Presenter: Thais H. Tittanegro

Abstract n°1649

Category: Immunology

Title: Acute liver injury results in temporal changes in hepatic macrophage pool

Presenter: Anna Bujko

Abstract n°1653

Category: Immunology

Title: Sustained delivery of IL-10 using innovative cell-based platform for immune-mediated hepatitis

Presenter: Sofia Brites Boss

Abstract n°1909

Category: Immunology

Title: Immunoepitidome of isolated patient-derived hepatocytes in Hepatitis B viral infection and hepatocellular carcinoma

Presenter: Sonja Buschow

Abstract n°1929

Category: Immunology

Title: Discovery of conserved HDV-specific CD8+ T-cell epitopes in HDV/HBV co-infection

Presenter: Valerie Oberhardt

Abstract n°1983

Category: Immunology

Title: HLA-B*27-restricted CD8+ T-cell response against hepatitis B virus: viral escape as central mechanism of T-cell failure

Presenter: Elahe Salimi Alizei

Abstract n°2154

Category: Immunology

Title: Characterization of in-vitro responses to different immune modulation of HBV core18-specific vs HBV pol455-specific CD8+ T cells

Presenter: Elmira Aliabadi

Abstract n°2173

Category: Immunology

Title: Treatment with GSK3228836 leads to HBsAg reduction and induction of interferon gamma related proteins and chemokines in a Phase 2a, randomized, double-blind, placebo-controlled study

Presenter: Shihyun You

Abstract n°2307

Category: Immunology

Title: Ex vivo immune checkpoint blockade differentially regulates IFN-gamma and IL-2 responses in HBV-specific T cells across clinical HBV phases

Presenter: Conan Chua

Abstract n°2339

Category: Immunology

Title: Impact of hepatitis B core-related antigen (HBcrAg) level on HBV specific CD4+ and CD8+ T cell responses in HBeAg negative patients with chronic hepatitis B virus infection

Presenter: Elmira Aliabadi

Abstract n°2456

Category: Immunology

Title: Transient Kupffer cell response to microbial components is critically regulated through expression of A20

Presenter: Christian Zwicker

Abstract n°279

Category: Liver development, physiology and regeneration

Title: Ablation of liver FXR results in an increased colonic mucus barrier in mice

Presenter: Noortje IJssennagger

Abstract n°687

Category: Liver development, physiology and regeneration

Title: A MET-agonistic antibody mimicking hepatocyte growth factor accelerates liver regeneration and improves survival in mice undergoing carbon tetrachloride exposure and partial hepatectomy

Presenter: Kuai Ma

Abstract n°943

Category: Liver development, physiology and regeneration

Title: Single-nucleus RNA-seq2 reveals a functional crosstalk between liver donation and ploidy

Presenter: Kelvin Yin

Abstract n°1154

Category: Liver development, physiology and regeneration

Title: Influence of human fecal bacteria's secretome in the maturation and function of the liver

Presenter: Joana Inês Almeida

Abstract n°1290

Category: Liver development, physiology and regeneration

Title: Integrin Alpha FG-GAP Repeat Containing 1 (ITFG1) knockdown enhances liver regeneration and attenuates chronic liver damage related liver fibrosis

Presenter: Viktoriia Iakovleva

Abstract n°1356

Category: Liver development, physiology and regeneration

Title: Hypoxia-induced liver angiogenesis rescues survival upon small for size hepatectomy in mice

Presenter: Maxime De Rudder

Abstract n°2234

Category: Liver development, physiology and regeneration

Title: In vitro Transplantation of Biliary Organoids Support Hepatic Differentiation and proliferation in Chronic Liver Injury

Presenter: Impreet Kaur

Abstract n°116

Category: Liver transplantation and hepatobiliary surgery: Clinical aspects

Title: Neutralizing antibodies against SARS-CoV-2 in cirrhotic patients waiting for liver transplantation

Presenter: Margherita Saracco

Abstract n°161

Category: Liver transplantation and hepatobiliary surgery: Clinical aspects

Title: Radiology-histopathology discordance in Hepatocellular cancer and its impact on post-transplant outcome

Presenter: Islam Mohamed

Abstract n°186

Category: Liver transplantation and hepatobiliary surgery: Clinical aspects

Title: Real-world experience of mTOR inhibitors in liver transplant recipients in a region where living donation is predominant

Presenter: Pil Soo Sung

Abstract n°212

Category: Liver transplantation and hepatobiliary surgery: Clinical aspects

Title: Early Renal Dysfunction Post Liver Transplant Predicts Long-term Adjudicated Cardiovascular Events

Presenter: Ramzi Hassouneh

Abstract n°351

Category: Liver transplantation and hepatobiliary surgery: Clinical aspects

Title: Liver transplantation for NAFLD cirrhosis : early overall patient survival is good

Presenter: François Villeret

Abstract n°353

Category: Liver transplantation and hepatobiliary surgery: Clinical aspects

Title: Disease recurrence after liver transplantation for NAFLD cirrhosis : just wait!

Presenter: François Villeret

Abstract n°364

Category: Liver transplantation and hepatobiliary surgery: Clinical aspects

Title: Waitlist outcomes for alcoholic hepatitis are more favorable than for other candidates with high Model for End-stage Liver Disease score in the current era

Presenter: Therese Bittermann

Abstract n°530

Category: Liver transplantation and hepatobiliary surgery: Clinical aspects

Title: Chances of renal recovery in liver only transplant recipients who were eligible for simultaneous liver-kidney transplant

Presenter: Jiawei Cui

Abstract n°594

Category: Liver transplantation and hepatobiliary surgery: Clinical aspects

Title: Incidental Cholangiocarcinoma in Liver Transplantation

Presenter: Nawaz Safdar

Abstract n°841

Category: Liver transplantation and hepatobiliary surgery: Clinical aspects

Title: Elevated donor-derived cell-free DNA during subclinical T-cell mediated rejection after liver transplantation

Presenter: Anna Katharina Baumann

Abstract n°922

Category: Liver transplantation and hepatobiliary surgery: Clinical aspects

Title: a novel score to risk stratify and optimize use of liver graft among patients with grade 3 acute on chronic liver failure

Presenter: Ashwani Singal

Abstract n°935

Category: Liver transplantation and hepatobiliary surgery: Clinical aspects

Title: Liver transplantation for severe alcoholic hepatitis: a multicentre Italian study

Presenter: Giacomo Germani

Abstract n°1126

Category: Liver transplantation and hepatobiliary surgery: Clinical aspects

Title: Patients with MELD exceptions have higher access to liver transplantation and lower waiting list mortality: the Swiss nationwide experience

Presenter: Melisa Dirchwolf

Abstract n°1133

Category: Liver transplantation and hepatobiliary surgery: Clinical aspects

Title: Post-transplant outcomes of previously refused liver grafts: a 10-years nationwide experience

Presenter: Chiara Becchetti

Abstract n°1168

Category: Liver transplantation and hepatobiliary surgery: Clinical aspects

Title: Graft survival following retransplantation - a large single centre retrospective analysis

Presenter: James Morgan

Abstract n°1169

Category: Liver transplantation and hepatobiliary surgery: Clinical aspects

Title: Changes in the profile and outcomes of paediatric liver transplantation in the United States

Presenter: Maria Stepanova

Abstract n°1459

Category: Liver transplantation and hepatobiliary surgery: Clinical aspects

Title: Recipient age influences the short- and long-term survival after liver transplant: results of the French national cohort 2007-2017

Presenter: Marianne Latournerie

Abstract n°1496

Category: Liver transplantation and hepatobiliary surgery: Clinical aspects

Title: Impact of bacterial infections prior liver transplantation on post-transplant outcomes in patients with cirrhosis

Presenter: Simone Incicco

Abstract n°1523

Category: Liver transplantation and hepatobiliary surgery: Clinical aspects

Title: Significantly higher mortality post liver transplantation in patients with psychosocial risk factors

Presenter: Jeevan Barn

Abstract n°1773

Category: Liver transplantation and hepatobiliary surgery: Clinical aspects

Title: Clinical value of surveillance biopsies in pediatric liver transplantation: A single center experience with > 800 biopsies

Presenter: Brittany Rocque

Abstract n°1971

Category: Liver transplantation and hepatobiliary surgery: Clinical aspects

Title: Factors associated with unplanned intensive care unit readmission following liver transplantation

Presenter: Marcus Robertson

Abstract n°2001

Category: Liver transplantation and hepatobiliary surgery: Clinical aspects

Title: Covid - 19 in Liver Transplant Recipients: A National Cohort

Presenter: Gökhan Kabaçam

Abstract n°2121

Category: Liver transplantation and hepatobiliary surgery: Clinical aspects

Title: The impact of COVID-19 on liver transplant (LT) centers across the world during the first wave: a Multisociety Survey (EASL-ESOT/ELITA-ILTS)

Presenter: Francesco Paolo Russo

Abstract n°2211

Category: Liver transplantation and hepatobiliary surgery: Clinical aspects

Title: Long-term survival after living donor liver transplantation in primary sclerosing cholangitis

Presenter: Timur Liwinski

Abstract n°2425

Category: Liver transplantation and hepatobiliary surgery: Clinical aspects

Title: Complete response after biological downstaging in patients with hepatocellular carcinoma: XXL-like prioritization for liver transplantation or "wait and see" strategy?

Presenter: Alessandro Vitale

Abstract n°246

Category: Liver transplantation and hepatobiliary surgery: Experimental

Title: CD44v6+gp38+ large extracellular vesicles in gall bladder survival prognosis - a pilot study

Presenter: Bingduo Wang

Abstract n°982

Category: Liver transplantation and hepatobiliary surgery: Experimental

Title: Development of a novel rat bioreactor to facilitate manufacture of human hepatocyte cell therapies for the treatment of patients with severe liver diseases

Presenter: Raymond Hickey

Abstract n°1119

Category: Liver transplantation and hepatobiliary surgery: Experimental

Title: Anti-apoptotic effect of mycophenolate mofetil in human hepatocytes cultures

Presenter: Razvan Iacob

Abstract n°1207

Category: Liver transplantation and hepatobiliary surgery: Experimental

Title: Selective hypoxia-inducible-factor stabilisation alleviates hepatocellular steatosis and ballooning in a rodent model of 70% liver resection

Presenter: Samuele Iesari

Abstract n°1346

Category: Liver transplantation and hepatobiliary surgery: Experimental

Title: Double negative T cells mediate CD39-dependent protection in hepatic ischemia and reperfusion injury

Presenter: Hua Jin

Abstract n°1422

Category: Liver transplantation and hepatobiliary surgery: Experimental

Title: Longitudinal monitoring of bioengineered whole liver constructs using a novel perfusion bioreactor

Presenter: Sara Campinoti

Abstract n°250

Category: Liver tumours: Clinical aspects except therapy

Title: prognostic value of a nomogram predicting microvascular invasion for patients with hepatocellular carcinoma

Presenter: Liying Ren

Abstract n°409

Category: Liver tumours: Clinical aspects except therapy

Title: Cause of Death and Cause-Specific Mortality in Primary Liver Cancer: Temporal Trends in a Hepatitis B Virus Endemic Area

Presenter: Bo Hyun Kim

Abstract n°498

Category: Liver tumours: Clinical aspects except therapy

Title: Predicting the outcome of patients with hepatocellular carcinoma treated with immunotherapy - the CRAFTY score

Presenter: Bernhard Scheiner

Abstract n°707

Category: Liver tumours: Clinical aspects except therapy

Title: Thyroid disease and hepatocellular carcinoma survival. A Danish nationwide cohort study

Presenter: Linda Skibsted Kornerup

Abstract n°750

Category: Liver tumours: Clinical aspects except therapy

Title: Two trans-arterial chemo-embolizations during liver transplantation waiting list and absence of complete radiological response: time for a systemic strategy?

Presenter: Edoardo Poli

Abstract n°1065

Category: Liver tumours: Clinical aspects except therapy

Title: External validation of LCR1-LCR2, a multivariate HCC risk calculator, in patients with chronic hepatitis C

Presenter: Thierry Poynard

Abstract n°1090

Category: Liver tumours: Clinical aspects except therapy

Title: The impacts of gender differences in muscle mass and adipose tissue on the outcomes of hepatocellular carcinoma after surgical resection

Presenter: Pei-Chang Lee

Abstract n°1101

Category: Liver tumours: Clinical aspects except therapy

Title: Glucose variability and risk of hepatocellular carcinoma in diabetic patients: A nationwide population-based study

Presenter: Jeong-Ju Yoo

Abstract n°1147

Category: Liver tumours: Clinical aspects except therapy

Title: Global burden of major gastrointestinal cancers and its association with socioeconomic development status, 1990-2019

Presenter: Jin-Shui Pan

Abstract n°1153

Category: Liver tumours: Clinical aspects except therapy

Title: Weight variations and level of estrogen exposure predict the evolution of hepatocellular adenomas

Presenter: Alix DEMORY

Abstract n°1164

Category: Liver tumours: Clinical aspects except therapy

Title: External validation of the Toronto hepatocellular carcinoma risk index in a Swedish population

Presenter: Hanne Åström

Abstract n°1238

Category: Liver tumours: Clinical aspects except therapy

Title: Natural history and clinical impact of non-neoplastic portal vein thrombosis in cirrhotics with hepatocellular carcinoma

Presenter: Sarah Shalaby

Abstract n°1275

Category: Liver tumours: Clinical aspects except therapy

Title: Significance of TERT genetic alterations and telomere length in hepatocellular carcinoma

Presenter: Jin Seoub Kim

Abstract n°1289

Category: Liver tumours: Clinical aspects except therapy

Title: Cirrhosis regression based on both Enhanced Liver Fibrosis (ELF) and Fibrotest after direct-acting hepatitis C therapeutics corresponded to a lower incidence rate of hepatocellular carcinoma (HCC) below the cost-effective threshold for surveillance

Presenter: Winston Dunn

Abstract n°1704

Category: Liver tumours: Clinical aspects except therapy

Title: Is alcohol only-related hepatocellular carcinoma so frequent? A cluster analysis of 12,841 hepatocellular carcinomas.

Presenter: Charlotte Costentin

Abstract n°1729

Category: Liver tumours: Clinical aspects except therapy

Title: Risk based HCC surveillance has the potential to minimise patient harm

Presenter: Chris Curran

Abstract n°2070

Category: Liver tumours: Clinical aspects except therapy

Title: Discriminatory changes in circulating lipid and small molecule metabolites in patients with MAFLD associated hepatocellular cancer

Presenter: rohini sharma

Abstract n°2181

Category: Liver tumours: Clinical aspects except therapy

Title: Abdominal ultrasound and alpha-foetoprotein for the diagnosis of hepatocellular carcinoma. A diagnostic test accuracy Cochrane review

Presenter: Agostino Colli

Abstract n°2223

Category: Liver tumours: Clinical aspects except therapy

Title: Proposal and validation of a novel scoring system for hepatocellular carcinomas beyond curability borders: Unresectable hepatocellular carcinoma prognostic index

Presenter: Coskun Ozer Demirtas

Abstract n°2242

Category: Liver tumours: Clinical aspects except therapy

Title: Incidence of Hepatocellular carcinoma in patients with Non-Alcoholic Fatty Liver Disease. A systematic Review, Meta-Analysis and Metaregression

Presenter: Marco Sanduzzi Zamparelli

Abstract n°2364

Category: Liver tumours: Clinical aspects except therapy

Title: The added value of PIVKA-II levels over AFP in patients with hepatocellular carcinoma undergoing locoregional treatment

Presenter: Massimo Iavarone

Abstract n°133

Category: Liver tumours: Experimental and pathophysiology

Title: Repression of fatty acid oxidation in steatohepatic-HCC is mediated by E2F1 and E2F2 transcription factors

Presenter: Francisco Gonzalez-Romero

Abstract n°179

Category: Liver tumours: Experimental and pathophysiology

Title: MicroRNA-27a-3p modulates FoxO1 to induce tumor-like phenotypes in CCA

Presenter: Lea Duwe

Abstract n°196

Category: Liver tumours: Experimental and pathophysiology

Title: Chronic liver damage favours induction of CD44v6 epithelial cells and subsequent liver carcinoma formation

Presenter: Akshaya Srikanth

Abstract n°336

Category: Liver tumours: Experimental and pathophysiology

Title: Differential requirement of RAS-dependent signaling pathways in tumor development and differentiation in murine liver cancer

Presenter: Carina Rupp

Abstract n°541

Category: Liver tumours: Experimental and pathophysiology

Title: Molecular characterization of HCC in Mongolia delineates unique genomic features

Presenter: Laura Torrens

Abstract n°615

Category: Liver tumours: Experimental and pathophysiology

Title: Identification of IGF2 as genomic driver and actionable therapeutic target in hepatoblastoma

Presenter: Jordi Abril-Fornaguera

Abstract n°699

Category: Liver tumours: Experimental and pathophysiology

Title: Immune classification of hepatocellular carcinoma based on new molecular features: the inflamed class

Presenter: Carla Montironi

Abstract n°906

Category: Liver tumours: Experimental and pathophysiology

Title: Molecular plasticity underlies cisplatin resistance and tumor recurrence in hepatoblastoma

Presenter: Theo Hirsch

Abstract n°920

Category: Liver tumours: Experimental and pathophysiology

Title: immuno-responsive classification of hepatocellular carcinomas as a potential surrogate for precision immuno-oncology

Presenter: Jihyun An

Abstract n°1118

Category: Liver tumours: Experimental and pathophysiology

Title: Metabolic reprogramming in a c-Myc/h-Ras transgenic mouse model of hepatocellular carcinoma

Presenter: Marina Serra

Abstract n°1304

Category: Liver tumours: Experimental and pathophysiology

Title: Targeting tumor-initiating cells and compensatory YAP pathway activation to overcome sorafenib-induced resistance in hepatocellular carcinoma

Presenter: Darko Castven

Abstract n°1352

Category: Liver tumours: Experimental and pathophysiology

Title: Study on the mechanism of chemokine CCL21 mediating IRBIT in the malignant biological behavior of liver cancer

Presenter: Jlanhong Ding

Abstract n°1629

Category: Liver tumours: Experimental and pathophysiology

Title: Influence on cancer cell energy metabolism by pharmacological inhibition of the histone modifying lysine-specific demethylase 1

Presenter: Jie Wang

Abstract n°1752

Category: Liver tumours: Experimental and pathophysiology

Title: Human antigen R (HuR) SUMOylation fine-tunes hepatocellular carcinoma (HCC) progression by modulating the expression of mitochondrial mRNAs

Presenter: Sofia Lachiondo-Ortega

Abstract n°1771

Category: Liver tumours: Experimental and pathophysiology

Title: The expressions of CCNB1, CDC20 and CENPF is both peripheral blood and liver is associated with anti-tumour immunity in HCC

Presenter: Zhenlin Huang

Abstract n°1825

Category: Liver tumours: Experimental and pathophysiology

Title: Programmed Death-Ligand 1 protein is preferentially expressed in tumor-associated macrophages in peritumoral regions of hepatocellular carcinoma

Presenter: Pil Soo Sung

Abstract n°1948

Category: Liver tumours: Experimental and pathophysiology

Title: Metabolic rewiring by increased mitochondrial respiration drives immune evasion in liver cancer

Presenter: Naroa Goikoetxea-Usandizaga

Abstract n°1949

Category: Liver tumours: Experimental and pathophysiology

Title: Role of hypoxia-inducible factors 1alpha and 2alpha in prognosis and sorafenib chemoresistance in hepatocarcinoma

Presenter: Carolina Méndez-Blanco

Abstract n°1957

Category: Liver tumours: Experimental and pathophysiology

Title: Resistance to sorafenib in hepatocarcinoma: role of BCL2 interacting protein 3 promoter hypermethylation

Presenter: Paula Fernández-Palanca

Abstract n°1969

Category: Liver tumours: Experimental and pathophysiology

Title: Abnormal glycosphingolipid patterns in human cholangiocarcinoma stem-like subset

Presenter: Mirella Pastore

Abstract n°2227

Category: Liver tumours: Experimental and pathophysiology

Title: Diagnostic and prognostic value of miR-16, miR-146a and miR-192 in exosomes of hepatocellular and liver cirrhosis patients

Presenter: Thorben Fründt

Abstract n°2375

Category: Liver tumours: Experimental and pathophysiology

Title: Dynamics of endothelial progenitor cells in patients with advanced hepatocellular carcinoma

Presenter: Claudia Campani

Abstract n°75

Category: Liver tumours: Therapy

Title: Irreversible electroporation vs radiofrequency ablation for hepatocellular carcinoma: A single centre propensity matched comparison

Presenter: Elliot Freeman

Abstract n°295

Category: Liver tumours: Therapy

Title: Checkmate 040: long-term efficacy and safety of nivolumab in patients with Child-Pugh B advanced hepatocellular carcinoma: associations between baseline biomarker analyses and outcomes

Presenter: Ana Matilla

Abstract n°573

Category: Liver tumours: Therapy

Title: TIAM1, a potential synthetic lethal gene and candidate therapeutic target for hepatocellular carcinoma

Presenter: Chalerm sin Permtersin

Abstract n°574

Category: Liver tumours: Therapy

Title: Pre-transplant AFP > 25.5 is associated with a higher risk of HCC recurrence after liver transplantation for patients meeting Milano criteria

Presenter: Bianca Magro

Abstract n°591

Category: Liver tumours: Therapy

Title: Higher number of transarterial treatments might have detrimental effects on the overall survival of patients eventually receiving systemic treatments

Presenter: Vito Sansone

Abstract n°767

Category: Liver tumours: Therapy

Title: comparison of hbv-related hcc incidence between entecavir and tenofovir treated cohorts: a population-based study

Presenter: Sichan He

Abstract n°777

Category: Liver tumours: Therapy

Title: Real-world outcomes of patients with hepatocellular carcinoma treated with transarterial radioembolization: results from CIRT, a large European prospective observational study

Presenter: Frank Kolligs

Abstract n°857

Category: Liver tumours: Therapy

Title: Kinetics of the neutrophil-lymphocyte ratio during PD-1 inhibition as a prognostic factor in advanced hepatocellular carcinoma

Presenter: Won-Mook Choi

Abstract n°945

Category: Liver tumours: Therapy

Title: Radiological and pathological response to neoadjuvant Nivolumab in patients with BCLC A HCC treated by curative percutaneous irreversible electroporation: preliminary report from the NIVOLEP trial (NCT03630640)

Presenter: Pierre Nahon

Abstract n°972

Category: Liver tumours: Therapy

Title: Safety and efficacy of holmium-166 radioembolisation in hepatocellular carcinoma: preliminary results from the HEPAR Primary study

Presenter: Margot Reinders-Hut

Abstract n°1010

Category: Liver tumours: Therapy

Title: Evaluation of cardiovascular events in patients with hepatocellular carcinoma treated with sorafenib in the clinical practice: CARDIO-SOR study.

Presenter: Lorena Carballo Folgoso

Abstract n°1046

Category: Liver tumours: Therapy

Title: Serum levels of CXCL13 are an independent predictor of survival following resection of biliary tract cancer

Presenter: Sven H Loosen

Abstract n°1124

Category: Liver tumours: Therapy

Title: Hepatocellular carcinoma recurrence after direct-acting antiviral therapy for hepatitis C virus. A systematic review and meta-analysis.

Presenter: Leonardo Frazzoni

Abstract n°1142

Category: Liver tumours: Therapy

Title: Duration of response and outcomes in advanced hepatocellular carcinoma patients with objective response to sorafenib: role of subsequent treatment.

Presenter: Kuo-Wei Huang

Abstract n°1145

Category: Liver tumours: Therapy

Title: A phase Ib study of pembrolizumab following trans-arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): PETAL

Presenter: Thomas Talbot

Abstract n°1209

Category: Liver tumours: Therapy

Title: Multibipolar radiofrequency ablation versus liver resection for the treatment of hepatocellular carcinoma within Milan criteria developed on advanced fibrosis/cirrhosis: a multicentric study on 1060 patients

Presenter: francois cauchy

Abstract n°1263

Category: Liver tumours: Therapy

Title: Impact of metabolic syndrome and non-alcoholic fatty liver disease in outcomes and tolerance after percutaneous multibipolar radiofrequency ablation for early hepatocellular carcinoma

Presenter: Thi Thu Nga Nguyen

Abstract n°1312

Category: Liver tumours: Therapy

Title: The impact of betablocker treatment on cancer prognosis in patients with advanced hepatocellular carcinoma receiving sorafenib treatment

Presenter: Lorenz Balcar

Abstract n°1351

Category: Liver tumours: Therapy

Title: Preliminary experience on safety of cabozantinib in recurrent hepatocellular carcinoma after liver transplantation. A case series

Presenter: Federica Invernizzi

Abstract n°1399

Category: Liver tumours: Therapy

Title: Results of the therapeutic cancer vaccine HepaVac-101 clinical trial in HCC patients

Presenter: Luigi Buonaguro

Abstract n°1420

Category: Liver tumours: Therapy

Title: Molecular markers of response to anti-pd1 therapy in advanced hepatocellular carcinoma

Presenter: Philipp Haber

Abstract n°1745

Category: Liver tumours: Therapy

Title: Equal overall survival in elderly patients with hepatocellular carcinoma receiving palliative treatment

Presenter: Thorben Fründt

Abstract n°1801

Category: Liver tumours: Therapy

Title: Evolutionary learning derived clinical-radiomic models for predicting early recurrence of hepatocellular carcinoma after surgical resection

Presenter: I-Cheng Lee

Abstract n°1856

Category: Liver tumours: Therapy

Title: Anti-tumor activity of TRN-000546, a liver-distributed monophosphate prodrug of FdUMP, in orthotopic liver tumor models

Presenter: Martijn Fenaux

Abstract n°1883

Category: Liver tumours: Therapy

Title: A Novel Prognostic Calculator to Optimize Individualized Treatment for Patients with HCC within the Milan the Milan Criteria.

Presenter: Ningning Zhang

Abstract n°2075

Category: Liver tumours: Therapy

Title: Aspirin and the risk of hepatocellular carcinoma in chronic liver disease: A systematic review and meta-analysis

Presenter: Jin Lin Tan

Abstract n°2190

Category: Liver tumours: Therapy

Title: A humanized Claudin-1 specific monoclonal antibody for treatment of hepatocellular carcinoma

Presenter: Natascha Roehlen

Abstract n°2401

Category: Liver tumours: Therapy

Title: Tailoring the management of HCC during the COVID-19 pandemic: a single center comparative analysis of 4 periods during 2020 versus 2019

Presenter: Massimo Iavarone

Abstract n°2408

Category: Liver tumours: Therapy

Title: The Number of Small Hepatocellular Carcinoma Nodules in Patients within the Alpha-Fetoprotein Score before Liver Transplantation Is a Prognostic Risk Factor

Presenter: Alina Pascale

Abstract n°138

Category: Molecular and cellular biology

Title: Rifaximin regulates nitrogen detoxification in a PXR-independent manner in human small intestinal organoids

Presenter: Koos de Wit

Abstract n°334

Category: Molecular and cellular biology

Title: A context-dependent role of c-myc in liver regeneration and hepatocarcinogenesis in chronic liver injury

Presenter: Silke Marhenke

Abstract n°375

Category: Molecular and cellular biology

Title: A profibrotic role for the orphan G-protein coupled receptor 176 during hepatic stellate cell activation

Presenter: Vincent De Smet

Abstract n°387

Category: Molecular and cellular biology

Title: Loss of cholangiocyte primary cilia drives reorganisation of the biliary tree and accelerates tumorigenesis

Presenter: Scott Waddell

Abstract n°608

Category: Molecular and cellular biology

Title: Multicellular primary mouse liver spheroids for DILI, NAFLD, NASH and fibrosis studies

Presenter: Elise Anne van Os

Abstract n°778

Category: Molecular and cellular biology

Title: The FXR-RXR interaction inhibits FXR isoform-specific gene activation in liver cells

Presenter: Jose Miguel Ramos Pittol

Abstract n°895

Category: Molecular and cellular biology

Title: cell cycle-regulatory genetic aberrations and their prognostic implications in early-stage hepatocellular carcinomas

Presenter: Jihyun An

Abstract n°901

Category: Molecular and cellular biology

Title: A murine model of FGFR2 fusion driven intrahepatic cholangiocarcinoma to delineate mechanism of therapeutic response and resistance to FGFR inhibitors

Presenter: Gajanan Kendre

Abstract n°1027

Category: Molecular and cellular biology

Title: A low carbohydrate diet partially prevents the hepatic hystological damage of hepatocyte OGT-deficient mice.

Presenter: Lucia Parlati

Abstract n°1355

Category: Molecular and cellular biology

Title: hepatic o-glcNacetylated-p53 as a hub integrating the glucose counter regulatory response and insulin-suppressed gluconeogenesis.

Presenter: María J González Rellán

Abstract n°1357

Category: Molecular and cellular biology

Title: Role of ASCT2 and KGA for ammonia-induced astrocyte senescence

Presenter: Olivia Knappe

Abstract n°1414

Category: Molecular and cellular biology

Title: A hypothalamus-liver axis regulates hepatic glucose homeostasis and lipid metabolism dysfunctions in an intraperitoneal treatment with olanzapine in male mice

Presenter: Vítor Ferreira

Abstract n°1606

Category: Molecular and cellular biology

Title: FXR agonists increase liver-derived serum alkaline phosphatase by species-specific pharmacologic mechanisms independent of cholestasis

Presenter: Justin Schumacher

Abstract n°1615

Category: Molecular and cellular biology

Title: Role of cytosolic phospholipase A2 and 5-lipoxygenase for ammonia-induced astrocyte senescence

Presenter: Philipp Heimers

Abstract n°1645

Category: Molecular and cellular biology

Title: SZN-043, a hepatocyte-targeted R-spondin mimetic, promotes robust hepatocyte proliferation and zonal gene expression changes in mice

Presenter: Russell Fletcher

Abstract n°1887

Category: Molecular and cellular biology

Title: Signal regulatory protein alpha promotes immune escape of hepatocellular carcinoma through mediating T-cells apoptosis

Presenter: Dongbo Chen

Abstract n°19

Category: NAFLD: Clinical aspects except therapy

Title: Modeling Disease Burden of Nonalcoholic Fatty Liver Disease (NAFLD) in Japan

Presenter: Junko Tanaka

Abstract n°33

Category: NAFLD: Clinical aspects except therapy

Title: Association between sarcopenic obesity and nonalcoholic fatty liver disease and fibrosis detected by fibroscan

Presenter: Karn Wijarnpreecha

Abstract n°293

Category: NAFLD: Clinical aspects except therapy

Title: Life expectancy and risk of cardiovascular disease in non-alcoholic fatty liver disease: a population-based cohort study

Presenter: Ying Shang

Abstract n°381

Category: NAFLD: Clinical aspects except therapy

Title: relevance of psychosocial biomarkers on therapeutic adherence in patients with non-alcoholic fatty liver disease

Presenter: Jesús Funuyet-Salas

Abstract n°441

Category: NAFLD: Clinical aspects except therapy

Title: Low alcohol consumption is associated with a decreased frequency of cirrhosis and hepatocellular carcinoma in a cohort of NAFLD outpatients

Presenter: Bernardo Stefanini

Abstract n°445

Category: NAFLD: Clinical aspects except therapy

Title: association of mafld with mortality in patients with covid-19 in méxico

Presenter: Martín Uriel Vázquez Medina

Abstract n°534

Category: NAFLD: Clinical aspects except therapy

Title: Pharmacokinetics of tropifexor, a potent farnesoid X receptor agonist, are similar in subjects with mild, moderate, and severe hepatic impairment: results from a multi-centre, open-label, single-dose study

Presenter: Rowan Stringer

Abstract n°566

Category: NAFLD: Clinical aspects except therapy

Title: Association between hepatic fat and subclinical vascular disease burden in the general population

Presenter: Xinting Cai

Abstract n°571

Category: NAFLD: Clinical aspects except therapy

Title: Relationship between hepatic venous pressure gradient and presence of decompensation in non-alcoholic fatty liver disease

Presenter: Octavi Bassegoda

Abstract n°612

Category: NAFLD: Clinical aspects except therapy

Title: Lean NAFLD from the General French Population have more Severe Liver Disease and Poorer Clinical Outcomes (NASH-CO Study)

Presenter: Oumarou NABI

Abstract n°614

Category: NAFLD: Clinical aspects except therapy

Title: Additive Effects of Diabetes and NAFLD on Liver Disease Severity and Clinical Outcomes in the General Population (NASH-CO Study)

Presenter: Oumarou NABI

Abstract n°630

Category: NAFLD: Clinical aspects except therapy

Title: Undiagnosed obstructive sleep apnoea is a major component in NAFLD quality of life impairment

Presenter: Wenhao Li

Abstract n°635

Category: NAFLD: Clinical aspects except therapy

Title: Increased serum ferritin levels predict long-term mortality in patients with NAFLD

Presenter: Angelo Armandi

Abstract n°685

Category: NAFLD: Clinical aspects except therapy

Title: The benefits of the novel nomenclature of metabolic fatty liver disease

Presenter: Álvaro Santos-Laso

Abstract n°711

Category: NAFLD: Clinical aspects except therapy

Title: Binge Eating Disorder is associated with an unfavourable body mass composition in patients with Non-Alcoholic fatty liver disease

Presenter: Roberta Forlano

Abstract n°719

Category: NAFLD: Clinical aspects except therapy

Title: Carriage of CYP2E1rs2070673:A is associated with higher prevalence of nonalcoholic steatohepatitis in patients with biopsy-proven nonalcoholic fatty liver disease

Presenter: Hong-Lei Ma

Abstract n°819

Category: NAFLD: Clinical aspects except therapy

Title: Real-world assessment of NAFLD stages using FibroScan in the US population and diabetes subpopulation based on data from NHANES 2017-2018

Presenter: Mazen Nouredin

Abstract n°825

Category: NAFLD: Clinical aspects except therapy

Title: Use of machine learning to develop a NAFLD screening tool using demographic, clinical and FibroScan data from the NHANES 2017-2018 database

Presenter: Birol Emir

Abstract n°831

Category: NAFLD: Clinical aspects except therapy

Title: Liver related and extrahepatic events in patients with nonalcoholic fatty liver disease: a competing risk analysis

Presenter: Grazia Pennisi

Abstract n°950

Category: NAFLD: Clinical aspects except therapy

Title: A serum metabolic fingerprint may predict advanced fibrosis due to NAFLD in a cohort of diabetic patients

Presenter: Roberta Forlano

Abstract n°969

Category: NAFLD: Clinical aspects except therapy

Title: Successful implementation of a weight loss intervention pathway for non-alcoholic fatty liver disease patients by advanced practice hepatology providers with obesity training

Presenter: Vicki Shah

Abstract n°1030

Category: NAFLD: Clinical aspects except therapy

Title: Different associations of variants in hydroxysteroid 17-beta dehydrogenase 13 with liver histology in ethnic Chinese

Presenter: Wen-yue Liu

Abstract n°1205

Category: NAFLD: Clinical aspects except therapy

Title: Prevalence of lean NAFLD vs lean MAFLD indicates a distinct risk of mortality

Presenter: Georg Semmler

Abstract n°1227

Category: NAFLD: Clinical aspects except therapy

Title: Poor Awareness of Non Alcoholic Fatty Liver Disease (NAFLD) Among Adults in the United States

Presenter: Zobair Younossi

Abstract n°1296

Category: NAFLD: Clinical aspects except therapy

Title: Pruritus, anxiety, and depression in patients with nonalcoholic fatty liver disease

Presenter: Albrecht Boehlig

Abstract n°1334

Category: NAFLD: Clinical aspects except therapy

Title: Mild alcohol consumption and risk for cardiovascular disease in patients with non-alcoholic steatohepatitis: data from a multicenter observational study.

Presenter: Savvoula Savvidou

Abstract n°1429

Category: NAFLD: Clinical aspects except therapy

Title: Clinical and prognostic differences between non-alcoholic fatty liver disease and mixed fatty liver disease

Presenter: Nicolau Vallejo-Senra

Abstract n°1436

Category: NAFLD: Clinical aspects except therapy

Title: ultra- processed food is associated with features of the metabolic syndrome and nafld related liver damage

Presenter: Dana Ivancovsky Wajcman

Abstract n°1526

Category: NAFLD: Clinical aspects except therapy

Title: The natural history of pediatric Non-alcoholic Fatty Liver Disease: interim analysis of a long term follow up study

Presenter: Laura Draijer

Abstract n°1611

Category: NAFLD: Clinical aspects except therapy

Title: AI-based histologic measurement of NASH (AIM-NASH): A drug development tool for assessing clinical trial endpoints

Presenter: Katy Wack

Abstract n°1667

Category: NAFLD: Clinical aspects except therapy

Title: Elevated serum bile acids in NASH patients with fibrosis in the context of their cholestatic genetic predisposition

Presenter: Monika Rau

Abstract n°1693

Category: NAFLD: Clinical aspects except therapy

Title: Frailty in non-alcoholic fatty liver cirrhosis in comparison to alcoholic cirrhosis, risk patterns and impact on prognosis

Presenter: Lubomir Skladany

Abstract n°1747

Category: NAFLD: Clinical aspects except therapy

Title: Spleen size does not correlate with stage of liver disease in people with non-alcoholic fatty liver disease

Presenter: Tessa Cacciottolo

Abstract n°1772

Category: NAFLD: Clinical aspects except therapy

Title: Metabolic-associated fatty liver disease is associated with length of stay but not worse survival post COVID-19

Presenter: Nicolas Goossens

Abstract n°1780

Category: NAFLD: Clinical aspects except therapy

Title: Incidence rates of select outcomes among patients with non-alcoholic steatohepatitis (NASH) and evidence of fibrosis or cirrhosis

Presenter: Monica Bertoia

Abstract n°1823

Category: NAFLD: Clinical aspects except therapy

Title: Body weight variability and the risk of cardiovascular outcomes in patients with nonalcoholic fatty liver disease: a nationwide cohort study

Presenter: Mi Na Kim

Abstract n°1865

Category: NAFLD: Clinical aspects except therapy

Title: Association between non-alcoholic fatty liver disease and extrahepatic malignancy

Presenter: mesut gumusoy

Abstract n°1880

Category: NAFLD: Clinical aspects except therapy

Title: Association between Non-alcoholic Fatty Liver Disease and the Risk of Dementia: A Nationwide Cohort Study

Presenter: Gi-Ae Kim

Abstract n°1904

Category: NAFLD: Clinical aspects except therapy

Title: Low skeletal muscle mass is a potential risk factor for lean non-alcoholic fatty liver disease in patients with non-alcoholic fatty liver disease

Presenter: Min Kyu Kang

Abstract n°1951

Category: NAFLD: Clinical aspects except therapy

Title: Novel MAFLD criteria identifies additional individual at risk for FIBROSIS: in depth comparison of MAFLD and NAFLD criteria in the Rotterdam Study.

Presenter: Laurens van Kleeef

Abstract n°2002

Category: NAFLD: Clinical aspects except therapy

Title: MAFLD-related cirrhosis is the main contributor to admissions for decompensated cirrhosis in intensive care unit. A single-center, 18-month experience.

Presenter: Marika Rudler

Abstract n°2074

Category: NAFLD: Clinical aspects except therapy

Title: Systematic review with meta-analysis: Non-Alcoholic Fatty Liver Disease (NAFLD) in Pregnancy

Presenter: Hydar El Jamaly

Abstract n°2326

Category: NAFLD: Clinical aspects except therapy

Title: Assessment of how modifiable and non-modifiable factors can impact fibrosis outcomes in non-alcoholic steatohepatitis patients: a 12-country real-world assessment

Presenter: Victoria Higgins

Abstract n°2328

Category: NAFLD: Clinical aspects except therapy

Title: NAFLD and colorectal adenoma - rather an association than causality

Presenter: Georg Semmler

Abstract n°2337

Category: NAFLD: Clinical aspects except therapy

Title: Prevalence estimation of significant fibrosis due to non-alcoholic steatohepatitis combining transient elastography and histology.

Presenter: Jesús Rivera

Abstract n°2343

Category: NAFLD: Clinical aspects except therapy

Title: Does fibrosis severity or diabetes status influence patient-reported lifestyle changes and degree of success among non-alcoholic steatohepatitis patients?

Presenter: Victoria Higgins

Abstract n°167

Category: NAFLD: Diagnostics and non-invasive assessment

Title: Derivation and validation of the NAFLD cirrhosis score (NCS) to distinguish bridging fibrosis from cirrhosis and to predict liver-related outcomes

Presenter: Christian Labenz

Abstract n°243

Category: NAFLD: Diagnostics and non-invasive assessment

Title: Comparative diagnostic accuracy of blood-based biomarkers for staging fibrosis in NAFLD: phase 1 results of the LITMUS project

Presenter: Jenny Lee

Abstract n°313

Category: NAFLD: Diagnostics and non-invasive assessment

Title: The prognosis is impaired in NAFLD patients with diabetes despite negative FIB4 <1.30

Presenter: Jerome Boursier

Abstract n°454

Category: NAFLD: Diagnostics and non-invasive assessment

Title: The use of age-specific cutoffs for FIB4 and NAFLD Fibrosis Score in a primary care setting finds over one-third of older diabetic patients are at high risk for NAFLD with advanced fibrosis

Presenter: Kendall Islam

Abstract n°538

Category: NAFLD: Diagnostics and non-invasive assessment

Title: Genome-scale metabolic modeling of human hepatocytes reveals dysregulation of glycosphingolipid pathways in progressive nonalcoholic fatty liver disease

Presenter: Partho Sen

Abstract n°555

Category: NAFLD: Diagnostics and non-invasive assessment

Title: Development and validation of Agile 3+: novel FibroScan based score for the diagnosis of advanced fibrosis in patients with non-alcoholic fatty liver disease

Presenter: Arun Sanyal

Abstract n°565

Category: NAFLD: Diagnostics and non-invasive assessment

Title: A prospective cohort study for the prevalence and screening policy of NAFLD in patients with T2DM in primary care

Presenter: Roberta Forlano

Abstract n°569

Category: NAFLD: Diagnostics and non-invasive assessment

Title: long term prognosis of patients with alcoholic disease or nafld according to metabolic syndrome or alcohol use

Presenter: Marie DECRAECKER

Abstract n°580

Category: NAFLD: Diagnostics and non-invasive assessment

Title: Modeling regional variation in the return on investment of VCTE for fatty liver disease (FLD) in the U.S.

Presenter: Mazen Nouredin

Abstract n°632

Category: NAFLD: Diagnostics and non-invasive assessment

Title: Prevalence of hepatic steatosis and advanced fibrosis in patients living with HIV in Germany

Presenter: Maurice Michel

Abstract n°751

Category: NAFLD: Diagnostics and non-invasive assessment

Title: M comes first: Impact of initial probe choice on diagnostic performance of vibration controlled transient elastography

Presenter: Valentin Blank

Abstract n°756

Category: NAFLD: Diagnostics and non-invasive assessment

Title: Combination treatments including semaglutide, cilofexor, and/or firsocostat lead to greater improvements in the FibroScan-AST (FAST) score compared to semaglutide alone in patients with non-alcoholic steatohepatitis

Presenter: Naim Alkhouri

Abstract n°769

Category: NAFLD: Diagnostics and non-invasive assessment

Title: A novel radiomics signature based on T2WI accurately predicts hepatic inflammation in individuals with biopsy-proven NAFLD: a derivation and independent validation study

Presenter: Zhongwei Chen

Abstract n°775

Category: NAFLD: Diagnostics and non-invasive assessment

Title: The effectiveness of a community based two-tier risk stratification pathway for non-alcoholic fatty liver disease

Presenter: Rebecca Harris

Abstract n°836

Category: NAFLD: Diagnostics and non-invasive assessment

Title: Patients with elevated Fibrosis-4 Index or NAFLD Fibrosis Score have higher rates of cardiovascular events: a post-hoc analysis from two large, randomised statin clinical trials in 18 814 patients

Presenter: Frank Tacke

Abstract n°866

Category: NAFLD: Diagnostics and non-invasive assessment

Title: Comparing traditional machine learning and deep learning models to Fibrosis-4 index in the prediction of non-alcoholic fatty liver disease-associated liver fibrosis

Presenter: Devon Y. Chang

Abstract n°916

Category: NAFLD: Diagnostics and non-invasive assessment

Title: Nonalcoholic fatty liver disease cardiovascular risk by metabolic subtype

Presenter: José M. Mato

Abstract n°919

Category: NAFLD: Diagnostics and non-invasive assessment

Title: Comparative diagnostic accuracy of blood-based biomarkers for diagnosing NASH: phase 1 results of the LITMUS project

Presenter: Yasaman Vali

Abstract n°941

Category: NAFLD: Diagnostics and non-invasive assessment

Title: Independent validation of Agile 4: novel FibroScan based score for the diagnosis of cirrhosis in patients with non-alcoholic fatty liver disease

Presenter: Jerome Boursier

Abstract n°944

Category: NAFLD: Diagnostics and non-invasive assessment

Title: Prognostic value of FibroScan based Agile 3+ and Agile 4 scores in patients with non-alcoholic fatty liver disease

Presenter: Jerome Boursier

Abstract n°980

Category: NAFLD: Diagnostics and non-invasive assessment

Title: Incidence rates of hepatobiliary outcomes among patients with non-alcoholic steatohepatitis based on fibrosis-4 score severity at baseline

Presenter: Lina Titievsky

Abstract n°1001

Category: NAFLD: Diagnostics and non-invasive assessment

Title: External Validation of the FAST Score as a Predictor of Fibrotic NASH in a Large Cohort of U.S. Adults with Biopsy-Proven NAFLD

Presenter: Naim Alkhouri

Abstract n°1020

Category: NAFLD: Diagnostics and non-invasive assessment

Title: Individualized polygenic risk score identifies NASH in the eastern Asia region: a derivation and validation study

Presenter: Feng Gao

Abstract n°1056

Category: NAFLD: Diagnostics and non-invasive assessment

Title: Biomarker screening strategies to identify fibrosing steatohepatitis cases for clinical trial recruitment in NAFLD

Presenter: Yasaman Vali

Abstract n°1106

Category: NAFLD: Diagnostics and non-invasive assessment

Title: Screening for compensated advanced chronic liver disease using refined Baveno VI elastography cutoffs in Asian patients with NAFLD

Presenter: Yu-Jie Zhou

Abstract n°1195

Category: NAFLD: Diagnostics and non-invasive assessment

Title: PNPLA3 and SERPINA1 are associated with liver disease severity in an unselected fatty liver disease cohort

Presenter: Lorenz Balcar

Abstract n°1202

Category: NAFLD: Diagnostics and non-invasive assessment

Title: Curriculum-based education in NAFLD/NASH improves knowledge, competence, and confidence among gastroenterologists

Presenter: Shari Dermer

Abstract n°1217

Category: NAFLD: Diagnostics and non-invasive assessment

Title: Hepatocellular carcinoma in patients with NASH is associated with a specific pattern of muscle fat infiltration: a first-order radiomics study based on MRI-PDFF

Presenter: Maxime Nachit

Abstract n°1220

Category: NAFLD: Diagnostics and non-invasive assessment

Title: PNPLA3 and TM6SF2 are neither associated with decreased cardiovascular nor increased liver-related mortality in the general population

Presenter: Lorenz Balcar

Abstract n°1336

Category: NAFLD: Diagnostics and non-invasive assessment

Title: The liver fibrosis marker PRO-C3 increases with fibrosis stage and is neither elevated in diabetics without liver disease nor in healthy obese subjects

Presenter: Elisabeth Erhardtsen

Abstract n°1453

Category: NAFLD: Diagnostics and non-invasive assessment

Title: Screening for non-alcoholic fatty liver disease (NAFLD)-related advanced fibrosis, real life data and comparison of two endocrinology-hepatology referral strategies

Presenter: Cyrielle Caussy

Abstract n°1518

Category: NAFLD: Diagnostics and non-invasive assessment

Title: Serum metabolomics-based steatohepatitis score for the non-invasive identification of patients with non-alcoholic steatohepatitis (NASH) in multiethnic, including type 2 diabetes mellitus population

Presenter: Pablo Ortiz

Abstract n°1556

Category: NAFLD: Diagnostics and non-invasive assessment

Title: Change in FibroScan-aspartate aminotransferase (FAST) score is associated with histological improvement in non-alcoholic steatohepatitis activity

Presenter: Vincent Wai-Sun Wong

Abstract n°1568

Category: NAFLD: Diagnostics and non-invasive assessment

Title: Longitudinal variability of noninvasive tests of fibrosis: Implications for treatment response monitoring in patients with NASH

Presenter: Quentin Anstee

Abstract n°1588

Category: NAFLD: Diagnostics and non-invasive assessment

Title: Comorbidity and healthcare utilization burden of patients diagnosed with non-alcoholic steatohepatitis based on fibrosis-4 score severity

Presenter: Lina Titievsky

Abstract n°1592

Category: NAFLD: Diagnostics and non-invasive assessment

Title: Individual patient data meta-analysis of the diagnostic performance of single and sequentially combined non-invasive tests in detecting advanced fibrosis

Presenter: Ferenc Mozes

Abstract n°1644

Category: NAFLD: Diagnostics and non-invasive assessment

Title: A deep learning approach to analysis of MRCP images predicts clinical events and progression to cirrhosis in patients with primary sclerosing cholangitis

Presenter: Aaditya Prakash

Abstract n°1648

Category: NAFLD: Diagnostics and non-invasive assessment

Title: Clinical utility of 30% relative decline in MRI-PDFF in predicting fibrosis regression in nonalcoholic fatty liver disease

Presenter: Nobuharu Tamaki

Abstract n°1689

Category: NAFLD: Diagnostics and non-invasive assessment

Title: Combination treatment with cilofexor and firsocostat leads to improvements in the FibroScan-AST (FAST) score which are associated with treatment response in patients with advanced fibrosis due to NASH

Presenter: Rohit Loomba

Abstract n°1714

Category: NAFLD: Diagnostics and non-invasive assessment

Title: Liver stiffness by vibration-controlled transient elastography predicts disease progression in patients with advanced fibrosis due to NASH

Presenter: Rohit Loomba

Abstract n°1777

Category: NAFLD: Diagnostics and non-invasive assessment

Title: The Metabolomics of Non-Alcoholic Fatty Liver Disease: Of Networks and Biomarkers

Presenter: Aidan McGlinchey

Abstract n°1808

Category: NAFLD: Diagnostics and non-invasive assessment

Title: Clinical care pathways for non-alcoholic fatty liver disease (NAFLD) in U.S. Veterans will improve resource utilization and linkage to specialty care

Presenter: Michael Fuchs

Abstract n°1826

Category: NAFLD: Diagnostics and non-invasive assessment

Title: Agreement in non-invasive fibrosis risk assessments in a primary care NAFLD cohort

Presenter: Andrew Schreiner

Abstract n°1895

Category: NAFLD: Diagnostics and non-invasive assessment

Title: Evaluation of the Fibrosis-4 score for referral from primary care patients for NAFLD in Belgium

Presenter: Leen Heyens

Abstract n°1927

Category: NAFLD: Diagnostics and non-invasive assessment

Title: In vivo SPECT imaging of steatohepatitis in NAFLD preclinical models using VCAM-1 nanobody: a proof-of-concept study

Presenter: Maxime Nachit

Abstract n°1981

Category: NAFLD: Diagnostics and non-invasive assessment

Title: Non-invasive LIVERFAST transition rate to liver fibrosis is similar to that estimated with liver biopsy in NAFLD patients

Presenter: Victor de Lédinghen

Abstract n°2030

Category: NAFLD: Diagnostics and non-invasive assessment

Title: Screening of advanced liver fibrosis in patients with coronary arterial disease, the CORONASH Study

Presenter: Thierry Thévenot

Abstract n°2362

Category: NAFLD: Diagnostics and non-invasive assessment

Title: Fibrosis biomarker performance in NAFLD is markedly improved by BMI-specific cut-offs

Presenter: Sami Qadri

Abstract n°2369

Category: NAFLD: Diagnostics and non-invasive assessment

Title: Current non-invasive tests have suboptimal performance for the identification of candidates for pharmacological therapy for pre-cirrotic non-alcoholic steatohepatitis.

Presenter: Jesús Rivera

Abstract n°195

Category: NAFLD: Experimental and pathophysiology

Title: Role of Mcpip1 in obesity-induced hepatic steatosis as determined by myeloid and liver-specific conditional knockouts

Presenter: Natalia Pydyn

Abstract n°283

Category: NAFLD: Experimental and pathophysiology

Title: Transcriptomics identifies longitudinal biomarker gene signatures of NASH fibrosis regressors

Presenter: Christina Ebert

Abstract n°297

Category: NAFLD: Experimental and pathophysiology

Title: ATG7 genetic variants predispose to severe fatty liver disease

Presenter: Cristiana Bianco

Abstract n°470

Category: NAFLD: Experimental and pathophysiology

Title: Restoration of altered bile acid pool inhibits the development of nonalcoholic steatohepatitis

Presenter: Justine Gillard

Abstract n°475

Category: NAFLD: Experimental and pathophysiology

Title: Inactivation of ACSL5, an interacting protein of TM6SF2, results in decreased plasma TG and cholesterol without affecting hepatic lipids

Presenter: Fei Luo

Abstract n°550

Category: NAFLD: Experimental and pathophysiology

Title: serpina3c deficiency promotes high-fat diet-induced steatohepatitis through mediating necroptosis via β -catenin-foxo1 axis

Presenter: linglin qian

Abstract n°584

Category: NAFLD: Experimental and pathophysiology

Title: auto-aggressive cxc6+ cd8 t cells cause liver immune pathology in nash

Presenter: Michael Dudek

Abstract n°716

Category: NAFLD: Experimental and pathophysiology

Title: distinctive alterations of the hepatic unfolded protein response in models of diabetes and non-alcoholic fatty liver disease

Presenter: Bedair Dewidar

Abstract n°725

Category: NAFLD: Experimental and pathophysiology

Title: Effects of empagliflozin and L-ornithine L-aspartate on behaviour, cognitive function, and physical performance in mice with non-alcoholic steatohepatitis

Presenter: Veronika Prikhodko

Abstract n°768

Category: NAFLD: Experimental and pathophysiology

Title: A first-in-class small molecule targeting 17-beta-hydroxysteroid dehydrogenase 13 for the treatment of non-alcoholic steatohepatitis

Presenter: Ji Won Choi

Abstract n°1028

Category: NAFLD: Experimental and pathophysiology

Title: Suppression of insulin-induced gene 1 (INSIG1) function restrains NASH progression by promoting hepatic lipid remodelling

Presenter: Vian Azzu

Abstract n°1037

Category: NAFLD: Experimental and pathophysiology

Title: inhibition of atg3 ameliorates liver steatosis by increasing sirt1 in an autophagic-independent action

Presenter: Eva Novoa

Abstract n°1150

Category: NAFLD: Experimental and pathophysiology

Title: The hepatic IKK-NFkB axis induces liver steatosis by increasing de novo lipogenesis and cholesterol synthesis

Presenter: Andries Heida

Abstract n°1235

Category: NAFLD: Experimental and pathophysiology

Title: Proteomics Signature of Advanced Fibrosis in Non-alcoholic Steatohepatitis (NASH) using Data-independent Acquisition (DIA) Mass Spectrometry

Presenter: Thomas Jeffers

Abstract n°1369

Category: NAFLD: Experimental and pathophysiology

Title: Non-alcoholic fatty liver disease in a rodent model of bariatric surgery with different bypass lengths

Presenter: Paula Richwien

Abstract n°1407

Category: NAFLD: Experimental and pathophysiology

Title: No impact of non-alcoholic fatty liver disease severity on hepatic and adipose tissue mitochondrial respiration but hepatic respiration increases after bariatric surgery

Presenter: Julie Steen Pedersen

Abstract n°1504

Category: NAFLD: Experimental and pathophysiology

Title: An independent blinded review of suspected drug-induced liver injury (DILI) in nonalcoholic steatohepatitis (NASH) patients by a panel of pathologists and hepatologists: lessons learned from the seladelpar hepatotoxicity review committee (SHRC)

Presenter: Paul Watkins

Abstract n°1524

Category: NAFLD: Experimental and pathophysiology

Title: Acetyl-CoA metabolism drives epigenome change in liver steatosis leading to widespread abnormal transcription, DNA damage and promotion of hepatocarcinogenetic pathways

Presenter: Neil Youngson

Abstract n°1547

Category: NAFLD: Experimental and pathophysiology

Title: Steatosis, inflammasome upregulation and fibrosis are attenuated in microRNA-155 deficient mice in a diet-induced model of NASH

Presenter: Mrigya Babuta

Abstract n°1626

Category: NAFLD: Experimental and pathophysiology

Title: Rilpivirine-induced anti-inflammatory effects in non-alcoholic fatty liver disease involve the inhibition of CCL2/CCR2 axis

Presenter: Ángela B. Moragrega

Abstract n°1727

Category: NAFLD: Experimental and pathophysiology

Title: Combination therapy of lanifibranor and firsocostat further improves steatohepatitis and fibrosis compared to monotherapy in a diet-induced murine model of NASH

Presenter: Guillaume Wettstein

Abstract n°1746

Category: NAFLD: Experimental and pathophysiology

Title: Cilofexor and firsocostat treatment is associated with widespread changes in the hepatic transcriptome in NASH patients with advanced fibrosis

Presenter: Yevgeniy Gindin

Abstract n°1753

Category: NAFLD: Experimental and pathophysiology

Title: Implication of the Patatin-like phospholipase domain-containing 3 I148M mutation on hepatic stellate cells mitochondrial dysfunction and profibrogenic potential

Presenter: Elisabetta Caon

Abstract n°1797

Category: NAFLD: Experimental and pathophysiology

Title: Effect of seladelpar and CB-0406 combination therapy on obesity, liver fibrosis and steatosis in a diet-induced obese (DIO) mouse model of biopsy-confirmed non-alcoholic steatohepatitis (NASH) with fibrosis

Presenter: Charles McWherter

Abstract n°1839

Category: NAFLD: Experimental and pathophysiology

Title: The Association of Dietary Factors and Physical Activity with Sarcopenia in Non-Alcoholic Fatty Liver Disease (NAFLD)

Presenter: James Paik

Abstract n°1849

Category: NAFLD: Experimental and pathophysiology

Title: A3907, a novel orally available inhibitor of the apical sodium-dependent bile acid transporter, improves key clinical markers of non-alcoholic steatohepatitis in obese diet-induced and biopsy-confirmed mouse models

Presenter: Peter Akerblad

Abstract n°1897

Category: NAFLD: Experimental and pathophysiology

Title: Men and women display different predictive biomarkers of NASH: a machine learning approach

Presenter: Gerard Baiges

Abstract n°1916

Category: NAFLD: Experimental and pathophysiology

Title: Co-stimulatory signals mediated by ICOS/ICOS-L dyad influence the differentiation of liver NASH-associated macrophages (NAMs)

Presenter: Laila lavanya Gadipudi

Abstract n°1942

Category: NAFLD: Experimental and pathophysiology

Title: Blockade of IL-1 signaling in hepatocytes reduces tumor growth in a mouse model of NAFLD-related HCC

Presenter: Nadine Gehrke

Abstract n°1986

Category: NAFLD: Experimental and pathophysiology

Title: The rs599839 A>G variant disentangles cardiovascular risk and hepatocellular carcinoma in NAFLD patients

Presenter: Marica Meroni

Abstract n°2033

Category: NAFLD: Experimental and pathophysiology

Title: TM6SF2/PNPLA3/MBOAT7 loss-of-function genetic variants impact on NAFLD development and progression both in patients and in in vitro models

Presenter: Miriam Longo

Abstract n°2055

Category: NAFLD: Experimental and pathophysiology

Title: The I148M PNPLA3 variant mitigates Niacin beneficial effects: how the genetic screening in Non-alcoholic Fatty Liver Disease (NAFLD) patients gains value

Presenter: Erika Paolini

Abstract n°2123

Category: NAFLD: Experimental and pathophysiology

Title: Liver Biopsy Graph Neural Networks for automated histologic scoring using the NASH CRN system

Presenter: Amaro Taylor

Abstract n°2161

Category: NAFLD: Experimental and pathophysiology

Title: Human hepatocyte PNPLA3-148M exacerbates rapid non-alcoholic fatty liver disease development in chimeric mice

Presenter: Mohammad Kabbani

Abstract n°2186

Category: NAFLD: Experimental and pathophysiology

Title: Imaging by Desorption electrospray ionization mass spectrometry detects changes in lobular patterns of lipids in non-alcoholic fatty liver disease

Presenter: Patcharamon Seubnooch

Abstract n°2210

Category: NAFLD: Experimental and pathophysiology

Title: A 3D in vitro screening-based discovery approach for selecting and prioritizing NASH drug candidates

Presenter: Radina Kostadinova

Abstract n°2276

Category: NAFLD: Experimental and pathophysiology

Title: Ripk3 depletion improves mitochondrial bioenergetics and function in experimental NAFLD

Presenter: Tawhidul Islam

Abstract n°2322

Category: NAFLD: Experimental and pathophysiology

Title: Exposure to environmental contaminants is associated with sex-specific disturbances of hepatic lipid metabolism in non-alcoholic fatty liver disease

Presenter: Matej Orešič

Abstract n°2411

Category: NAFLD: Experimental and pathophysiology

Title: Hepatocyte-specific deletion of ERK5 worsens insulin resistance in a murine model of nonalcoholic fatty liver disease

Presenter: Giulia Lori

Abstract n°2412

Category: NAFLD: Experimental and pathophysiology

Title: Combining non-selective beta blockers with FXR agonists towards ameliorating intestinal barrier dysfunction in NASH

Presenter: Yasmeen Attia

Abstract n°2450

Category: NAFLD: Experimental and pathophysiology

Title: First in class, orally active Toll-like receptor signaling inhibitor mosedipimod (PLAG) attenuates molecular, biochemical and histological features of nonalcoholic steatohepatitis (NASH) in vitro and in vivo

Presenter: Michael Charlton

Abstract n°159

Category: NAFLD: Therapy

Title: Target engagement and evidence of efficacy with PXL770, a novel direct AMP-Kinase activator, in a 4-week PK/PD trial in patients with NAFLD

Presenter: Vlad Ratziu

Abstract n°230

Category: NAFLD: Therapy

Title: Semaglutide in patients with non-alcoholic steatohepatitis: subgroup analysis of a randomised, placebo-controlled phase 2 trial

Presenter: Sven Francque

Abstract n°231

Category: NAFLD: Therapy

Title: Effect of subcutaneous semaglutide on quality-of-life in patients with non-alcoholic steatohepatitis

Presenter: Manuel Romero Gomez

Abstract n°337

Category: NAFLD: Therapy

Title: Funded referral to a commercial weight loss provider is effective in achieving weight loss in Non-alcoholic fatty liver disease

Presenter: Iain Hay

Abstract n°393

Category: NAFLD: Therapy

Title: MET642, an FXR agonist with a unique chemotype, demonstrates a safe, sustained profile in a 14-day randomized study in healthy subjects

Presenter: Richard Pencek

Abstract n°427

Category: NAFLD: Therapy

Title: Human proof-of-concept in non-alcoholic liver disease (NAFLD) patients with PXL770, a novel first-in-class direct AMP-kinase activator -- STAMP-NAFLD Phase 2a trial

Presenter: Kenneth Cusi

Abstract n°435

Category: NAFLD: Therapy

Title: Hyperammonemia and intrahepatic microcirculation disorders and its correction at the nonalcoholic steatohepatitis patients with initial stages of liver fibrosis

Presenter: Tatiana Ermolova

Abstract n°627

Category: NAFLD: Therapy

Title: Hepatic magnesium accumulation upon cyclin M4 (CNNM4) silencing improves NASH

Presenter: Jorge Simón

Abstract n°668

Category: NAFLD: Therapy

Title: Safety and pharmacokinetics of DUR-928 in hepatic function impaired subjects

Presenter: Jaymin Shah

Abstract n°681

Category: NAFLD: Therapy

Title: Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator (SPPARM alpha), improves liver stiffness by MRE and serum liver and lipid parameters in NAFLD; a randomized, double-blind, placebo-controlled phase 2 trial

Presenter: Rohit Loomba

Abstract n°757

Category: NAFLD: Therapy

Title: Fenofibrate is safe and mitigates increases in serum triglycerides in NASH patients treated with the combination of the ACC inhibitor firsocostat and the FXR agonist cilofexor: A randomized trial

Presenter: Eric Lawitz

Abstract n°787

Category: NAFLD: Therapy

Title: Anti-fibrotic potential of a novel long-acting Glucagon/GIP/GLP-1 triple agonist, HM15211, in preclinical models of fibrosis

Presenter: Jung Kuk Kim

Abstract n°838

Category: NAFLD: Therapy

Title: Combination of an acetyl-CoA carboxylase inhibitor and fibroblast growth factor 19 reduced tissue triglyceride content and fibrosis in human precision-cut liver slices

Presenter: Wen-Wei Tsai

Abstract n°849

Category: NAFLD: Therapy

Title: Treatment of a non-alcoholic steatohepatitis cirrhotic patients with resmetirom: baseline characteristics and effects on safety, biomarkers and imaging

Presenter: Stephen Harrison

Abstract n°851

Category: NAFLD: Therapy

Title: Study on multi-target engagement effect of a novel long-acting Glucagon/GIP/GLP-1 triple agonist, HM15211, in animal model of NASH

Presenter: Jong Suk Lee

Abstract n°889

Category: NAFLD: Therapy

Title: Digital pathology with artificial intelligence analyses reveal new dynamics of treatment-induced fibrosis regression in nonalcoholic steatohepatitis

Presenter: Nikolai V. Naoumov

Abstract n°931

Category: NAFLD: Therapy

Title: Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers is associated with lower risk of hepatocellular carcinoma and cirrhotic complications in patients with non-alcoholic fatty liver disease

Presenter: Xinrong Zhang

Abstract n°981

Category: NAFLD: Therapy

Title: Aldafermin reduces hydrophobic bile acids in a 24-week, randomized, double-blind, placebo-controlled, multicenter study in patients with nonalcoholic steatohepatitis

Presenter: Arun Sanyal

Abstract n°1034

Category: NAFLD: Therapy

Title: The pan-PPAR agonist lanifibranor significantly improves cardiovascular risk biomarkers in patients with NASH

Presenter: Sven Francque

Abstract n°1044

Category: NAFLD: Therapy

Title: Lanifibranor therapy improves markers of lipid metabolism, insulin resistance, liver injury and fibrosis in patients with NASH and F2 and F3 fibrosis stages: a subgroup analysis of the phase 2b NATIVE study

Presenter: Sven Francque

Abstract n°1082

Category: NAFLD: Therapy

Title: Atherosclerotic cardiovascular risk assessment in a 24-week, randomized, double-blind, placebo-controlled study of aldafermin

Presenter: Nadege T. Gunn

Abstract n°1112

Category: NAFLD: Therapy

Title: Analysis of non-invasive biomarker tests in the Phase 2 FASCINATE-1 Study of FASN Inhibitor TVB-2640

Presenter: Marie O'Farrell

Abstract n°1198

Category: NAFLD: Therapy

Title: Efficacy Signals Of 4-Week Oral DUR-928 in NASH Subjects

Presenter: Eric Lawitz

Abstract n°1314

Category: NAFLD: Therapy

Title: The role of reduction in liver fat content (MRI-PDFF) and ALT in predicting treatment response in NASH: A secondary analysis of the randomized, controlled BALANCED trial

Presenter: Rohit Loomba

Abstract n°1359

Category: NAFLD: Therapy

Title: Anti-oxidant, anti-inflammatory, and anti-fibrotic properties of triterpenic acids and phenylpropanoids on in vitro models of non-alcoholic steatohepatitis

Presenter: Noel Salvoza

Abstract n°1627

Category: NAFLD: Therapy

Title: Treatment of NAFLD with intermittent calorie restriction, low-carb high-fat diet or standard dietary advice - a randomized controlled trial

Presenter: Magnus Holmer

Abstract n°1762

Category: NAFLD: Therapy

Title: Correlation between changes in liver fat content and improvements in serum markers of liver injury, fibrosis, metabolism, and in histologic parameters following treatment with efruxifermin

Presenter: Stephen Harrison

Abstract n°1769

Category: NAFLD: Therapy

Title: Interim analysis from a 72 week, double-blind, placebo-controlled, multicenter, paired liver biopsy study of endoscopic sleeve gastropasty in patients with non-alcoholic steatohepatitis (NASH)

Presenter: Javier Abad Guerra

Abstract n°1819

Category: NAFLD: Therapy

Title: KS-356, a novel inhibitor of TGF-beta superfamily signaling, improves obesity and obesity-related hepatic steatosis by inhibition of TGF-beta/Smad3 signaling pathway in high-fat diet-induced mice

Presenter: Kiso Pahk

Abstract n°1851

Category: NAFLD: Therapy

Title: Significant lipid lowering by ASC41oral tablet, a liver targeted THR β agonist, in a phase I randomized, double-blind, placebo controlled single- and multiple-ascending dose study

Presenter: Jinzi J. Wu

Abstract n°1908

Category: NAFLD: Therapy

Title: Significant Improvement of NAFLD Activity Scores and Liver Fibrosis by ASC41, a Selective THR- β Agonist, in High Fat Diet Induced NASH SD Rats

Presenter: JINZI WU

Abstract n°1961

Category: NAFLD: Therapy

Title: Significant improvement of NAFLD activity scores and liver fibrosis by ASC42, a novel non-steroidal FXR agonist, in high fat diet induced NASH mice

Presenter: Jinzi J. Wu

Abstract n°1992

Category: NAFLD: Therapy

Title: Genetic ablation of TMEM86B (lysoplasmalogenase) modulates endogenous plasmalogens and is a potential therapy for non-alcoholic fatty liver disease

Presenter: Sudip Paul

Abstract n°2006

Category: NAFLD: Therapy

Title: Anti-inflammatory and anti-fibrotic effects of icosabutate as mono- or combination therapy with a GLP-1 receptor agonist, a FXR agonist or an ACC inhibitor in a dietary mouse model of progressive fibrosis

Presenter: David A. Fraser

Abstract n°2099

Category: NAFLD: Therapy

Title: Development of a disease-mimicking model for NASH and liver fibrosis in a triple cell-type, spheroid-based liver-on-chip platform with microfluidics

Presenter: Geurt Stokman

Abstract n°2163

Category: NAFLD: Therapy

Title: Inhibition of integrin α V β 1 and α V β 6 by a small molecule inhibitor attenuated liver fibrosis and tumor formation in an advanced mouse NASH model

Presenter: Dipankar Bhattacharya

Abstract n°2192

Category: NAFLD: Therapy

Title: Neddylation inhibition reduces liver steatosis in MAFLD mice models by promoting hepatic fatty acid oxidation via DEPTOR-mTOR axis

Presenter: Marina Serrano-Macia

Abstract n°2287

Category: NAFLD: Therapy

Title: Oral LPCN 1144 treatment significantly reduced liver fat and key liver injury markers in biopsy confirmed NASH subjects: Results of a Phase 2 randomized controlled study

Presenter: Kilyoung Kim

Abstract n°2290

Category: NAFLD: Therapy

Title: Aminotransferase improvements in patients with non-alcoholic steatohepatitis are associated with fibrosis regression in the REGENERATE study

Presenter: Mary Rinella

Abstract n°2297

Category: NAFLD: Therapy

Title: BIO89-100 demonstrated robust reduction in liver fat fraction and liver fat volume (LFV) and favorable tolerability with weekly (QW) and every 2 weeks (Q2W) dosing in a Phase 1b/2a placebo-controlled proof of concept study in NASH

Presenter: Rohit Loomba

Abstract n°2312

Category: NAFLD: Therapy

Title: Novel liver-specific thymomimetics for the treatment of steatohepatitis

Presenter: Andrea Perra

Abstract n°2329

Category: NAFLD: Therapy

Title: High prevalence of low normal or overtly hypogonadal levels of testosterone observed in histologically established NASH subjects in LiFT Study

Presenter: Benjamin Bruno

Abstract n°2377

Category: NAFLD: Therapy

Title: Canagliflozin and Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus (CaNAFLD) - A Secondary Analysis of Two Randomized Controlled Trials

Presenter: Angel Borisov

Abstract n°507

Category: Non-invasive assessment of liver disease except NAFLD

Title: Von Willebrand factor for outcome prediction within different clinical stages of advanced chronic liver disease

Presenter: Bernhard Scheiner

Abstract n°818

Category: Non-invasive assessment of liver disease except NAFLD

Title: Transient splenic elastography predicts high-risk esophageal varices in patients with noncirrhotic portal hypertension

Presenter: Joel Silva

Abstract n°1047

Category: Non-invasive assessment of liver disease except NAFLD

Title: Jaundice detection by deep convolutional neural network using smartphone images

Presenter: Tung-Hung Su

Abstract n°1091

Category: Non-invasive assessment of liver disease except NAFLD

Title: CHES criteria for screening and monitoring of varices needing treatment: an international multicenter study

Presenter: Chuan Liu

Abstract n°1668

Category: Non-invasive assessment of liver disease except NAFLD

Title: Extracorporeal non-invasive assessment of the hepatobiliary function using novel bile acid derivatives with near-infrared fluorescence

Presenter: Jose Marin

Abstract n°1696

Category: Non-invasive assessment of liver disease except NAFLD

Title: Diagnostic Accuracy of Transient Elastography in Diagnosing Clinically Significant Portal Hypertension in Patients with Chronic Liver Disease: A Systematic Review and Meta-analysis

Presenter: Ashish Kumar

Abstract n°1899

Category: Non-invasive assessment of liver disease except NAFLD

Title: A novel liver-specific fibrosis biomarker, PRO-C18L, can predict response to antifibrotic treatment, with a peroxisome proliferator activated receptor - γ agonist, in patients with chronic hepatitis C

Presenter: Ida Villesen

Abstract n°1954

Category: Non-invasive assessment of liver disease except NAFLD

Title: Real-world assessment of the non-invasive ratio of exchangeable copper (REC) as a marker of Wilson's disease in a multicentric cohort of pediatric and adult patients.

Presenter: Cristina Molera Busoms

Abstract n°2094

Category: Non-invasive assessment of liver disease except NAFLD

Title: Quantitate MR can identify paediatric patients with quiescent disease who may benefit from a change in treatment

Presenter: Elizabeth Shumbayawonda

Abstract n°2184

Category: Non-invasive assessment of liver disease except NAFLD

Title: Serum miRNA profiling for the differential diagnosis of distal cholangiocarcinoma from pancreatic diseases

Presenter: André L. Simão

Abstract n°2319

Category: Non-invasive assessment of liver disease except NAFLD

Title: Validation of non-invasive criteria for diagnosis of clinically significant portal hypertension in compensated advanced chronic liver disease of different etiologies in an asian cohort

Presenter: Ankur Jindal

Abstract n°2370

Category: Non-invasive assessment of liver disease except NAFLD

Title: Evaluation of the newly proposed criteria for clinically significant portal hypertension using platelets and transient elastography

Presenter: Dr. Kristian Podrug

Abstract n°2386

Category: Non-invasive assessment of liver disease except NAFLD

Title: Dynamic liver function tests and liver elastography in cardiac amyloidosis - preliminary data from AmyKoS

Presenter: Sandra Ihne

Abstract n°190

Category: Nurses and Allied Health Professionals research in hepatology

Title: Patients with LIVER CIRRHOSIS - SATISFACTION in a NURSE-LED outpatient clinic

Presenter: Marie Louise Sjoedin Hamberg

Abstract n°205

Category: Nurses and Allied Health Professionals research in hepatology

Title: A new prediction equation for estimating body weight in cirrhotic patients with refractory ascites

Presenter: Bruna Cherubini Alves

Abstract n°511

Category: Nurses and Allied Health Professionals research in hepatology

Title: Health status perception and patient experience in liver cancer patients participating in Nurse-led Educational Programs

Presenter: Neus Llarch

Abstract n°686

Category: Nurses and Allied Health Professionals research in hepatology

Title: Suffering from the unpredictable illness in liver cirrhosis

Presenter: Maria Hjorth

Abstract n°798

Category: Nurses and Allied Health Professionals research in hepatology

Title: The impact of intervention by dedicated nurse upon the treatment of patients post DAA treatment for HCV

Presenter: Evelin Oxtrud

Abstract n°1193

Category: Nurses and Allied Health Professionals research in hepatology

Title: Lifestyle changes after cured Hepatitis C patients and adherence of a nurse-led liver cancer screening program

Presenter: Núria Granel

Abstract n°1221

Category: Nurses and Allied Health Professionals research in hepatology

Title: Importance of a clinical pharmacist specialized in hepatitis C treatment for the management of potential drug-drug interactions in a multidisciplinary ECHO® hepatitis C expert team

Presenter: Yaroslav Filippov

Abstract n°1353

Category: Nurses and Allied Health Professionals research in hepatology

Title: Randomized controlled study: investigation of the effect of exercise on liver function tests, fatigue and quality of life in patients with liver cirrhosis

Presenter: Hülya Keskin

Abstract n°1525

Category: Nurses and Allied Health Professionals research in hepatology

Title: Nurse intervention optimizes the care of patients with hepatocellular carcinoma under systemic treatment

Presenter: Gemma Iserte

Abstract n°1756

Category: Nurses and Allied Health Professionals research in hepatology

Title: Increased hospital presentations with alcohol-related disorders during the COVID-19 crisis in the United Kingdom

Presenter: Michelle Layton

Abstract n°183

Category: Public Health

Title: Exploring the relationship between maternal pre-pregnancy BMI and outcomes of NAFLD in young adulthood: a parental negative control study

Presenter: Kushala Abeysekera

Abstract n°199

Category: Public Health

Title: Get Tested LeEDs: Clinical impact and cost-effectiveness of opt-out emergency department testing for bloodborne viruses (BBVs)

Presenter: Elizabeth Smout

Abstract n°251

Category: Public Health

Title: Definition of healthy ranges for alanine aminotransferase levels: a 2020 update

Presenter: Serena Pelusi

Abstract n°260

Category: Public Health

Title: Risk factors for chronic hepatitis B among 0.5 million Chinese adults

Presenter: Elizabeth Hamilton

Abstract n°424

Category: Public Health

Title: Simplified test and treat protocols for population level screening and elimination of hepatitis B and hepatitis C in Uzbekistan

Presenter: Erkin Musabaev

Abstract n°425

Category: Public Health

Title: Modelling the potential effectiveness of different screening and treatment strategies for hepatitis c during pregnancy in Ukraine

Presenter: Nadia Hachicha Maalej

Abstract n°504

Category: Public Health

Title: Innovative linkage model to re-engage lost-to-follow-up individuals in the national hepatitis C elimination program of Georgia

Presenter: Amiran Gamkrelidze

Abstract n°533

Category: Public Health

Title: Healthcare restrictions due to COVID-19 impaired liver care, lowered patient satisfaction and increased liver-related mortality

Presenter: Lukas Hartl

Abstract n°539

Category: Public Health

Title: Promoting Hepatitis Virus Screening Test at Worksite in Japan Using Nudge Theory compared with Full Subsidies

Presenter: Masaaki Korenaga

Abstract n°551

Category: Public Health

Title: The effect of COVID-19 on the progress of the hepatitis C elimination program in Georgia

Presenter: Amiran Gamkrelidze

Abstract n°640

Category: Public Health

Title: Using the copula method to accurately estimate the impact of body mass index and alcohol consumption on liver disease

Presenter: Lise Retat

Abstract n°739

Category: Public Health

Title: Micro-elimination of Hepatitis C in prisons of Punjab, India

Presenter: Kanudeep kaur

Abstract n°785

Category: Public Health

Title: RECONVOCC : Can we recouvene chronic hepatitis C patients who were lost to follow-up ?

Presenter: Armand Abergel

Abstract n°821

Category: Public Health

Title: Usefulness of FIB-4 as a screening test for chronic liver disease in a university hospital

Presenter: Victor de Lédinghen

Abstract n°1035

Category: Public Health

Title: A novel approach to age cohort screening for hepatitis C in the primary care setting of a large urban health care setting with linkage to care

Presenter: David Bernstein

Abstract n°1072

Category: Public Health

Title: Food Insecurity is Associated with All-Cause Mortality in U.S. Adults with Nonalcoholic Fatty Liver Disease and Advanced Fibrosis

Presenter: Ani Kardashian

Abstract n°1158

Category: Public Health

Title: Baseline characteristics of a large multi-site chronic HBV electronic health record-based cohort in the UK

Presenter: Cori Campbell

Abstract n°1330

Category: Public Health

Title: Performance of screening strategies for primary prophylaxis of variceal bleeding in patients with compensated cirrhosis: a cost-effectiveness analysis

Presenter: Shanshan Lin

Abstract n°1341

Category: Public Health

Title: Active search to retrieve lost-to follow-up HCV patients (RELINK-C strategy): health and economic value

Presenter: Joan Martinez-Camprecios

Abstract n°1374

Category: Public Health

Title: Optimizing diagnostic algorithms to advance HCV elimination in Italy: A cost effectiveness evaluation

Presenter: Loreta Kondili

Abstract n°1381

Category: Public Health

Title: Effect of COVID-19 on alcohol use disorder among hospitalised patients: a retrospective cohort control study

Presenter: Mohsan Subhani

Abstract n°1421

Category: Public Health

Title: The 2010 HIV outbreak among people who inject drugs in Athens, Greece could have been prevented if the undetected 2009 HCV outbreak had been detected: A mathematical modeling study

Presenter: Ilias Gountas

Abstract n°1426

Category: Public Health

Title: A discrete choice experiment about patients' and clinicians' preferences for the meet-test-treat approach to HCV management

Presenter: Patrizio Pasqualetti

Abstract n°1431

Category: Public Health

Title: Value assessment of sofosbuvir-based regimens for (chronic) hepatitis C in Spain

Presenter: Rafael ESTEBAN

Abstract n°1480

Category: Public Health

Title: Epidemiological evaluation of the liver cirrhosis in Albania: comparison with the historical data and indications to antiviral treatment appropriateness

Presenter: Xhimi Tata

Abstract n°1551

Category: Public Health

Title: The Impact of COVID-19 Pandemic on Patients with Chronic Liver Disease (CLD): Data from the Global Registry

Presenter: Maria Stepanova

Abstract n°1572

Category: Public Health

Title: Screening and treatment of Hepatitis C virus in Hungarian prisons: 13 years of experience

Presenter: Klara Werling

Abstract n°1587

Category: Public Health

Title: Chronic liver disease and the risk of mortality after Covid-19: a national, retrospective, cohort study for 2020

Presenter: Vincent Mallet

Abstract n°1593

Category: Public Health

Title: The "Caserta Model": a way for HCV free Hospitals, a simplified procedure for HCV micro-elimination

Presenter: Vincenzo Messina

Abstract n°1624

Category: Public Health

Title: Planning the Hepatitis C elimination in Cyprus: A modeling study

Presenter: Ilias Gountas

Abstract n°1666

Category: Public Health

Title: Telemedicine improve HCV elimination among Italian people who use drugs: an innovative therapeutic model to increase the adherence to treatment into addiction care centers.

Presenter: VALERIO ROSATO

Abstract n°1713

Category: Public Health

Title: Liver Transplant Wait-List Trends in Young American Adults

Presenter: George Philip

Abstract n°1813

Category: Public Health

Title: General population testing for hepatitis B in Australia: a cost-effectiveness analysis

Presenter: Yinzong Xiao

Abstract n°1817

Category: Public Health

Title: Decreased hepatitis B and C testing in Ontario, Canada during the first wave of the COVID-19 pandemic

Presenter: Erin Mandel

Abstract n°1862

Category: Public Health

Title: Predictors of loss to follow-up in an outpatient cirrhotic population

Presenter: Joana Vieira Barbosa

Abstract n°1877

Category: Public Health

Title: Feasibility, effectiveness, and lessons learned from the introduction of decentralised HCV testing and treatment at primary healthcare clinics in three regions in Malaysia

Presenter: Sonjelle Shilton

Abstract n°1903

Category: Public Health

Title: SEAL program - Early detection of liver fibrosis and cirrhosis by screening of the general population

Presenter: Nagel Michael

Abstract n°1936

Category: Public Health

Title: A global systematic review of efforts to accelerate the elimination of hepatitis C virus (HCV) through micro-elimination

Presenter: Jeffrey Lazarus

Abstract n°1990

Category: Public Health

Title: The unmet needs of living with non-alcoholic steatohepatitis (NASH) in Europe and Canada: results from a multi-country survey

Presenter: Jeffrey Lazarus

Abstract n°2014

Category: Public Health

Title: The emergency department, a new setting for HBV screening in populations with limited linkage to the health care system in a high-income country

Presenter: Jordi Llaneras

Abstract n°2032

Category: Public Health

Title: Disclosure of non-alcoholic steatohepatitis (NASH) diagnosis and fear of discrimination: results from a multi-country survey

Presenter: Jeffrey Lazarus

Abstract n°2039

Category: Public Health

Title: Anticipated timing of hepatitis C virus elimination in the Netherlands and the impact of COVID-19

Presenter: Marleen van Dijk

Abstract n°2047

Category: Public Health

Title: HCV screening of immigrants at arrival: an opportunity to linkage to care of a population with limited access to health care system

Presenter: Mar Riveiro Barciela

Abstract n°2059

Category: Public Health

Title: Characterizing stigma related to non-alcoholic fatty liver disease (NAFLD) and obesity: a Twitter discourse analysis

Presenter: Jeffrey Lazarus

Abstract n°2081

Category: Public Health

Title: Feasibility, effectiveness, and lessons learnt from decentralized HCV testing and treatment models among the general population in Delhi, India

Presenter: Sonjelle Shilton

Abstract n°2093

Category: Public Health

Title: Micro-elimination of hepatitis C achieved in HIV co-infected persons in Slovenia: analysis of HCV infection in a national HIV cohort

Presenter: Jasna Cernosa

Abstract n°2097

Category: Public Health

Title: Impact of COVID-19 pandemic on referral of patients with liver disease to a liver transplant center

Presenter: Giacomo Germani

Abstract n°2103

Category: Public Health

Title: Changhua-Integrated Program to Stop Hepatitis C Infection (CHIPS-C) of Taiwan

Presenter: Tsung-Hui Hu

Abstract n°2108

Category: Public Health

Title: The global non-alcoholic fatty liver disease (NAFLD) preparedness index: are countries ready to tackle the challenge?

Presenter: Jeffrey Lazarus

Abstract n°2127

Category: Public Health

Title: The road to hepatitis C virus elimination: entering the final stretch or chasing a moving finish line?

Presenter: Ragnheidur H. Fridriksdottir

Abstract n°2131

Category: Public Health

Title: A clinical and molecular epidemiological survey of hepatitis C in Blantyre, Malawi suggests an historic mechanism of transmission

Presenter: Alexander Stockdale

Abstract n°2152

Category: Public Health

Title: Modelling clinical outcomes of NASH in the United States stratified by presence of type 2 diabetes

Presenter: Zobair Younossi

Abstract n°2202

Category: Public Health

Title: Mortality and cause of death in people with chronic hepatitis B - a nationwide register-based cohort study

Presenter: Signe Bollerup

Abstract n°2288

Category: Public Health

Title: Etiology of Cirrhosis in Turkey: A National Cohort Study

Presenter: Enver Ucbilek

Abstract n°2387

Category: Public Health

Title: Implementation of a coordinated hepatocellular carcinoma screening program in an outpatient liver center

Presenter: Joana Vieira Barbosa

Abstract n°2424

Category: Public Health

Title: An interactive, country specific, online tool to assess the cost-effectiveness of different hepatitis C testing pathways to inform hepatitis C elimination

Presenter: Madeline Adee

Abstract n°106

Category: Rare liver diseases (including paediatric and genetic)

Title: Social outcomes in patients with biliary atresia: a systematic review

Presenter: Emma Alexander

Abstract n°299

Category: Rare liver diseases (including paediatric and genetic)

Title: Clinical and radiological characterisation of Polycystic Liver Disease

Presenter: Benjamin Giles

Abstract n°323

Category: Rare liver diseases (including paediatric and genetic)

Title: Liver phenotype of adults with alpha-1 antitrypsin deficiency in the UK Biobank and in an international, multi-center cohort

Presenter: Malin Fromme

Abstract n°561

Category: Rare liver diseases (including paediatric and genetic)

Title: Recent portal venous system thrombosis associated with Cytomegalovirus disease: results of a multicenter study

Presenter: Chloé De Broucker

Abstract n°570

Category: Rare liver diseases (including paediatric and genetic)

Title: Portal vein recanalization for severe portal hypertension related to chronic non-cirrhotic extrahepatic portal vein obstruction: long term results

Presenter: Artru Florent

Abstract n°613

Category: Rare liver diseases (including paediatric and genetic)

Title: Prophylaxis of recurrent thrombosis by rivaroxaban in patients with non-cirrhotic chronic portal vein thrombosis (PVT): a multicentre randomized controlled study testing rivaroxaban vs no anticoagulation

Presenter: Aurélie Plessier

Abstract n°891

Category: Rare liver diseases (including paediatric and genetic)

Title: An innovative treatment for Primary Hyperoxaluria Type 1 based on specific gene correction and hepatic direct cell reprogramming

Presenter: Virginia Nieto-Romero

Abstract n°996

Category: Rare liver diseases (including paediatric and genetic)

Title: Non-invasive biomarkers for assessment of esophageal variceal bleeding risk in patients with non-cirrhotic portal hypertension

Presenter: hangfei xu

Abstract n°1108

Category: Rare liver diseases (including paediatric and genetic)

Title: Hepatic venous pressure gradient in non-cirrhotic portal hypertension — is it worth measuring ?

Presenter: hangfei xu

Abstract n°1172

Category: Rare liver diseases (including paediatric and genetic)

Title: liver trasplant for porto-sinusoidal vascular disease (psvd): long-term outcome

Presenter: Marta Magaz

Abstract n°1243

Category: Rare liver diseases (including paediatric and genetic)

Title: Direct oral anticoagulants (DOACs) for off-label use in patients with Budd Chiari Syndrome (BCS)

Presenter: Georg Semmler

Abstract n°1244

Category: Rare liver diseases (including paediatric and genetic)

Title: The prevalence of PSYCHIATRIC comorbidities in WILSON'S DISEASE

Presenter: Merjem Begic

Abstract n°1285

Category: Rare liver diseases (including paediatric and genetic)

Title: An integrated analysis of long-term clinical safety in maralixibat-treated participants with Alagille syndrome

Presenter: Rakesh Raman

Abstract n°1354

Category: Rare liver diseases (including paediatric and genetic)

Title: Wilson Disease is associated with prevalent neuropsychiatric comorbidity

Presenter: Eva Pfister

Abstract n°1396

Category: Rare liver diseases (including paediatric and genetic)

Title: cJun N-terminal kinase signaling prevents biliary cyst formation through a Caspase-8-dependent function of receptor-interacting serine/threonine kinase 1 during aging

Presenter: Katrin Mueller

Abstract n°1500

Category: Rare liver diseases (including paediatric and genetic)

Title: Dose adjustment of chelators based on urinary copper excretion after a drug free holiday - the first step to personalized medicine in patients with Wilson disease

Presenter: Karin Kozbial

Abstract n°1522

Category: Rare liver diseases (including paediatric and genetic)

Title: Voices of italian patients with Wilson's disease: results from a quality survey

Presenter: Massimo Zuin

Abstract n°1554

Category: Rare liver diseases (including paediatric and genetic)

Title: Rapid and durable effect of odevixibat on clinical and biochemical parameters of cholestasis in children with progressive familial intrahepatic cholestasis

Presenter: Richard Thompson

Abstract n°1641

Category: Rare liver diseases (including paediatric and genetic)

Title: Long-term treatment with odevixibat improves multiple sleep parameters in patients with progressive familial intrahepatic cholestasis: a pooled responder analysis from the phase 3 PEDFIC studies

Presenter: Richard Thompson

Abstract n°1665

Category: Rare liver diseases (including paediatric and genetic)

Title: Substantial clinical benefits with odevixibat treatment across progressive familial intrahepatic cholestasis genetic deficiencies: subgroup analysis of serum bile acids, pruritus, and safety using pooled data from the PEDFIC 1 and 2 studies

Presenter: Richard Thompson

Abstract n°1718

Category: Rare liver diseases (including paediatric and genetic)

Title: Genetic analysis and phenotypic correlation in ductal plate malformation

Presenter: Meha Bhuva

Abstract n°1722

Category: Rare liver diseases (including paediatric and genetic)

Title: Epidemiology and burden of Progressive Familial Intrahepatic Cholestasis: Systematic review

Presenter: Velichka Valcheva

Abstract n°1758

Category: Rare liver diseases (including paediatric and genetic)

Title: Circulating Fn14 is associated with pathogenic TH17 polarization in children with sclerosing cholangitis and inflammatory bowel disease

Presenter: Simon Lam

Abstract n°1809

Category: Rare liver diseases (including paediatric and genetic)

Title: Efficacy, safety, and tolerability of seladelpar in patients with compensated liver cirrhosis due to primary biliary cholangitis (PBC): a pooled analysis of phase 2 and phase 3 studies

Presenter: Stuart C Gordon

Abstract n°1811

Category: Rare liver diseases (including paediatric and genetic)

Title: Odevixibat effects on cholestasis-related parameters: Analysis of pooled data from the PEDFIC 1 and PEDFIC 2 studies in children with progressive familial intrahepatic cholestasis

Presenter: Richard Thompson

Abstract n°1828

Category: Rare liver diseases (including paediatric and genetic)

Title: Genetic mutation and cystic fibrosis-associated liver disease at the time of diagnosis in children: A correlational study

Presenter: ALEJANDRA SABILLON

Abstract n°1833

Category: Rare liver diseases (including paediatric and genetic)

Title: Odevixibat therapy improves clinically meaningful endpoints in children with progressive familial intrahepatic cholestasis: Data from the PEDFIC 1 and PEDFIC 2 trials

Presenter: Richard Thompson

Abstract n°1843

Category: Rare liver diseases (including paediatric and genetic)

Title: Pretreatment serum bile acid parameters and predictability of response to odevixibat, an ileal bile acid transport inhibitor, in children with progressive familial intrahepatic cholestasis

Presenter: Henkjan Verkade

Abstract n°1921

Category: Rare liver diseases (including paediatric and genetic)

Title: Factors related to liver impairment during SARS-CoV-2 infection

Presenter: Lidia Canillas

Abstract n°2040

Category: Rare liver diseases (including paediatric and genetic)

Title: Single-centre experience with follow up of patients with acute porphyria

Presenter: Barbora Nováková

Abstract n°2090

Category: Rare liver diseases (including paediatric and genetic)

Title: A 3-proteomic score to improve the clinical management of childhood liver cancer

Presenter: Carolina Armengol

Abstract n°2120

Category: Rare liver diseases (including paediatric and genetic)

Title: Treatment with seladelpar in patients with primary biliary cholangitis (PBC) and prior experience with obeticholic acid (OCA) or fibrates

Presenter: Aliya Gulamhusein

Abstract n°2204

Category: Rare liver diseases (including paediatric and genetic)

Title: Modeling phenotypic heterogeneity of Glycogen Storage Disease type Ia liver disease in mice by somatic CRISPR/Cas9-mediated gene editing

Presenter: Martijn Rutten

Abstract n°2324

Category: Rare liver diseases (including paediatric and genetic)

Title: Incidence and impact of PYLEPHEBITIS in PYOGENIC LIVER ABSCESS

Presenter: Nicolas Drilhon

Abstract n°2392

Category: Rare liver diseases (including paediatric and genetic)

Title: Liver Involvement is rare during COVID -19 Infection In Children

Presenter: Cigdem Arıkan

Abstract n°175

Category: Viral Hepatitis A, B, C, D, E: Virology

Title: A cell-based cccDNA reporter assay combined with functional genomics identifies YBX1 as HBV cccDNA host factor and antiviral target

Presenter: Gaëtan Ligat

Abstract n°258

Category: Viral Hepatitis A, B, C, D, E: Virology

Title: Helicases DDX5 and DDX17 regulate hepatitis B virus transcriptional fidelity and RNA processing in infected human primary hepatocytes

Presenter: Guillaume GIRAUD

Abstract n°469

Category: Viral Hepatitis A, B, C, D, E: Virology

Title: Study of the effect of the hepatitis D virus on the hepatitis B virus quasispecies in mice models by a next-generation sequencing approach

Presenter: Beatriz Pacín

Abstract n°526

Category: Viral Hepatitis A, B, C, D, E: Virology

Title: Real life kinetics of new HBV markers during treatment of chronic hepatitis D with bulevirtide

Presenter: Charlotte Pronier

Abstract n°595

Category: Viral Hepatitis A, B, C, D, E: Virology

Title: Preclinical antiviral profile of AB-836, a potent, highly selective hepatitis B virus capsid inhibitor

Presenter: Nagraj Mani

Abstract n°611

Category: Viral Hepatitis A, B, C, D, E: Virology

Title: Adaptation of hepatitis C virus to efficient infection of mouse hepatocytes

Presenter: julie sheldon

Abstract n°626

Category: Viral Hepatitis A, B, C, D, E: Virology

Title: assembly dynamics and infection efficacy of hepatitis b virus surface protein exchanges in the eight hepatitis d virus genotypes

Presenter: Wenshi Wang

Abstract n°700

Category: Viral Hepatitis A, B, C, D, E: Virology

Title: Farnesoid X receptor alpha ligands inhibit in vitro HDV replication and virion secretion and infectivity

Presenter: Christophe Ramière

Abstract n°820

Category: Viral Hepatitis A, B, C, D, E: Virology

Title: Viral factors and host response in chronic HDV infection

Presenter: Ester García-Pras

Abstract n°852

Category: Viral Hepatitis A, B, C, D, E: Virology

Title: Identification of novel host factors in the patho-biology of Hepatitis B Virus (HBV) infection

Presenter: Collins Oduor Owino

Abstract n°861

Category: Viral Hepatitis A, B, C, D, E: Virology

Title: Exploring host liver responses to Hepatitis B Virus at single cell resolution

Presenter: Balakrishnan Chakrapani Narmada

Abstract n°1021

Category: Viral Hepatitis A, B, C, D, E: Virology

Title: Immunogenicity and cytokine patterns of newly identified CD4 T cell epitopes within the three open reading frames of the hepatitis E virus

Presenter: Benedikt Csernalabics

Abstract n°1024

Category: Viral Hepatitis A, B, C, D, E: Virology

Title: recapitulating hepatitis e virus-host interactions and facilitating antiviral drug discovery in human liver organoids

Presenter: pengfei li

Abstract n°1062

Category: Viral Hepatitis A, B, C, D, E: Virology

Title: Identification and characterization of neutralizing human monoclonal antibodies against Hepatitis E virus

Presenter: Katja Dinkelborg

Abstract n°1305

Category: Viral Hepatitis A, B, C, D, E: Virology

Title: Mechanism of Action of Hepatitis B Virus S-antigen Transport-inhibiting Oligonucleotide Polymers (STOPSTM) Molecules.

Presenter: Cheng Kao

Abstract n°1450

Category: Viral Hepatitis A, B, C, D, E: Virology

Title: Secreted hepatitis B virus (HBV) RNA associates to extracellular vesicles in supernatant of infected hepatocytes

Presenter: Delphine Bousquet

Abstract n°1451

Category: Viral Hepatitis A, B, C, D, E: Virology

Title: Characterization of circulating hepatitis B virus (HBV) RNA in chronic hepatitis B (CHB) patients

Presenter: Doohyun Kim

Abstract n°1631

Category: Viral Hepatitis A, B, C, D, E: Virology

Title: A cell culture model of primary human hepatocytes derived from HBV-infected humanized mice for antiviral drug evaluation

Presenter: Jan-Hendrik Bockmann

Abstract n°1688

Category: Viral Hepatitis A, B, C, D, E: Virology

Title: Molecular mechanisms underlying the antiviral activity of a TLR2 agonist on HBV replication in hepatocytes

Presenter: Manon Desmares

Abstract n°1707

Category: Viral Hepatitis A, B, C, D, E: Virology

Title: Cloning and in vivo characterization of a new hepatitis D virus genotype 1 strain from a patient achieving sustained virus response to interferon alpha treatment

Presenter: Katja Giersch

Abstract n°1711

Category: Viral Hepatitis A, B, C, D, E: Virology

Title: Inducers of the NF- κ B pathways impair Hepatitis Delta virus (HDV) replication & strongly decrease progeny infectivity and spreading

Presenter: Julie Lucifora

Abstract n°1742

Category: Viral Hepatitis A, B, C, D, E: Virology

Title: IFN response blocks cell division-mediated HDV spread and suppresses HDV persistence when combined with antivirals abrogating de novo infection

Presenter: Zhenfeng Zhang

Abstract n°1907

Category: Viral Hepatitis A, B, C, D, E: Virology

Title: Viral interference in a hepatitis C virus and hepatitis E virus co-infection system

Presenter: Thomas Burkard

Abstract n°1917

Category: Viral Hepatitis A, B, C, D, E: Virology

Title: Significant in-Vitro and in-Vivo inhibition of HBsAg and HBV pgRNA with ASC42, a novel non-steroidal FXR agonist

Presenter: Jinzi Wu

Abstract n°1928

Category: Viral Hepatitis A, B, C, D, E: Virology

Title: Unexpected rising in the circulation of HBV complex profiles with HBsAg vaccine-escape mutations in HBV genotype-D: potential implications for HBsAg detection/quantification and vaccination strategies

Presenter: Lorenzo Piermatteo

Abstract n°1950

Category: Viral Hepatitis A, B, C, D, E: Virology

Title: An antibody microarray identifies epidermal growth factor receptor as a novel host factor of hepatitis E virus

Presenter: Jil Alexandra Schrader

Abstract n°1980

Category: Viral Hepatitis A, B, C, D, E: Virology

Title: Quantified integrated hepatitis B virus DNA in relation to other viral markers in chronic hepatitis B patients

Presenter: Robin Erken

Abstract n°2105

Category: Viral Hepatitis A, B, C, D, E: Virology

Title: Hepatitis B virus surface antigen expression determines hepatic immunity and Kupffer cell functions in HBV-transgenic mice

Presenter: Stefan Schefczyk

Abstract n°2135

Category: Viral Hepatitis A, B, C, D, E: Virology

Title: A specific deletion pattern in the preS1- and preS2-domain is associated with treatment induced HBsAg loss in chronic hepatitis B

Presenter: Maria Pfefferkorn

Abstract n°2145

Category: Viral Hepatitis A, B, C, D, E: Virology

Title: Conservation, variability and evolution of Hepatitis Delta virus in antigen coding region

Presenter: Beatriz Pacín

Abstract n°2293

Category: Viral Hepatitis A, B, C, D, E: Virology

Title: Low anti-HBc levels are associated with lower risk of virological relapse after discontinuation of nucleos(t)ide analogue therapy in HBe antigen negative patients.

Presenter: Valerie Ohlendorf

Abstract n°1844

Category: Viral hepatitis A/E: Clinical aspects

Title: Global burden of acute hepatitis and its association with socioeconomic development status, 1990-2019

Presenter: Jia You

Abstract n°218

Category: Viral hepatitis B/D: Clinical aspects except therapy

Title: incidence and resolution of steatohepatitis in patients receiving entecavir for chronic hepatitis b

Presenter: Yiwen Shi

Abstract n°266

Category: Viral hepatitis B/D: Clinical aspects except therapy

Title: Liver volume measurement predicts development of hepatic encephalopathy in chronic hepatitis b patients

Presenter: changhyun lee

Abstract n°408

Category: Viral hepatitis B/D: Clinical aspects except therapy

Title: Circulating HBV RNA correlates with intrahepatic covalently closed circular DNA (cccDNA) transcriptional activity in untreated and NUC-treated chronic hepatitis B (CHB) patients

Presenter: Barbara Testoni

Abstract n°415

Category: Viral hepatitis B/D: Clinical aspects except therapy

Title: exosomes with mir-574 transfer anti-hbv activity mediated by the interferon from macrophage to hbv-infected hepatocyte

Presenter: wenyu wu

Abstract n°420

Category: Viral hepatitis B/D: Clinical aspects except therapy

Title: A 3-antigen prophylactic hepatitis B virus vaccine confers rapid onset of protection in young adults, age 18-45, compared to a single-antigen hepatitis B virus vaccine

Presenter: Francisco Diaz-Mitoma

Abstract n°460

Category: Viral hepatitis B/D: Clinical aspects except therapy

Title: Persistent High HBsAg Levels Predict Lower Risk of Hepatocellular Carcinoma in HBeAg-seropositive Chronic Hepatitis B Patients

Presenter: Hsin-Che Lin

Abstract n°529

Category: Viral hepatitis B/D: Clinical aspects except therapy

Title: Clinical importance of a new, high-sensitivity HBcrAg assay for monitoring chronic hepatitis B and HBV reactivation

Presenter: Takako Inoue

Abstract n°654

Category: Viral hepatitis B/D: Clinical aspects except therapy

Title: VALIANT: A targeted long-read approach to study translocation and mRNA isoforms associated with HBV integration

Presenter: Cameron Soulette

Abstract n°665

Category: Viral hepatitis B/D: Clinical aspects except therapy

Title: Transcriptomic analyses reveal variation of liver inflammation across phases of chronic hepatitis B infection

Presenter: Ricardo Ramirez

Abstract n°676

Category: Viral hepatitis B/D: Clinical aspects except therapy

Title: An episode of detectable serum hepatitis B virus-DNA level does not affect risk of hepatic decompensation among untreated compensated cirrhosis patient with viral load of < 2,000 IU/mL

Presenter: Hye Won LEE

Abstract n°813

Category: Viral hepatitis B/D: Clinical aspects except therapy

Title: Prognosis of severe HBV reactivation in Western countries: role of the MELD score

Presenter: Edoardo Poli

Abstract n°887

Category: Viral hepatitis B/D: Clinical aspects except therapy

Title: HDV RNA replication is linked with higher serum concentrations of HBV cccDNA transcriptional activity markers - HBcrAg and pre-genomic HBV RNA

Presenter: Ivana Carey

Abstract n°900

Category: Viral hepatitis B/D: Clinical aspects except therapy

Title: Current and past infection of hepatitis B virus do not increase mortality in patients with COVID-19: a territory-wide cohort of 5,639 patients

Presenter: Terry Cheuk-Fung Yip

Abstract n°915

Category: Viral hepatitis B/D: Clinical aspects except therapy

Title: METABOLIC dysfunction associated FATTY LIVER disease and adverse clinical outcomes in patients with CHRONIC HEPATITIS B

Presenter: Laurens van Kleef

Abstract n°947

Category: Viral hepatitis B/D: Clinical aspects except therapy

Title: Immunogenetic diversity predicts viral control in chronic HBV (CHB) patients after discontinuation of direct antiviral treatment

Presenter: Marianne Tuefferd

Abstract n°1000

Category: Viral hepatitis B/D: Clinical aspects except therapy

Title: Association of Vitamin D receptor's Cdx-2 polymorphism and related haplotypes in patients with chronic hepatitis B infection in the inactive carrier and chronic hepatitis phases: a case-control study

Presenter: Prooksa Ananchuensook

Abstract n°1115

Category: Viral hepatitis B/D: Clinical aspects except therapy

Title: Clinical aspect of coronavirus disease 2019 (COVID-19) on HBV infected patients in term of Health Insurance Review & Assessment service data

Presenter: Young Kul Jung

Abstract n°1257

Category: Viral hepatitis B/D: Clinical aspects except therapy

Title: Combination drug interactions of hepatitis B virus (HBV) small interfering RNA (siRNA) and antisense oligonucleotides (ASO) in vitro and in vivo

Presenter: Hua Tan

Abstract n°1309

Category: Viral hepatitis B/D: Clinical aspects except therapy

Title: Alanine aminotransferase flares and seroclearance in chronic hepatitis B virus patients

Presenter: Shahed Iqbal

Abstract n°1340

Category: Viral hepatitis B/D: Clinical aspects except therapy

Title: Association between chronic hepatitis B infection and COVID-19: A nationwide case-control study

Presenter: Seong Hee Kang

Abstract n°1385

Category: Viral hepatitis B/D: Clinical aspects except therapy

Title: Risk of Hepatitis B Virus Reactivation in Patients Treated with PD-1 or PD-L1 Inhibitor for Non-Hepatocellular C ancer

Presenter: Sun Yoo

Abstract n°1510

Category: Viral hepatitis B/D: Clinical aspects except therapy

Title: Serum markers of HBV cccDNA transcriptional activity - HBcrAg and pre-genomic HBV RNA, pre-treatment HDV RNA and HDV genotype are useful markers in predicting treatment responses to pegylated interferon in HDV infection

Presenter: Ivana Carey

Abstract n°1519

Category: Viral hepatitis B/D: Clinical aspects except therapy

Title: Endoscopic surveillance of esophageal varices could be refined in HBV compensated cirrhotics taking Tenofovir or Entecavir: an 11-year real-life study

Presenter: Elisa Farina

Abstract n°1605

Category: Viral hepatitis B/D: Clinical aspects except therapy

Title: Detection of novel biomarkers in HBV-associated chronic hepatitis, liver fibrosis/cirrhosis, and hepatocellular carcinoma utilizing transcriptome sequencing technology

Presenter: dandan zhao

Abstract n°1622

Category: Viral hepatitis B/D: Clinical aspects except therapy

Title: Efficacy of hepatitis B virus vaccines HBVaxpro40 and Fendrix in patients with chronic liver disease in clinical practice

Presenter: Diana Horta

Abstract n°1725

Category: Viral hepatitis B/D: Clinical aspects except therapy

Title: Health-related quality of life and stigma related to chronic hepatitis B: a systematic literature review

Presenter: Vera Gielen

Abstract n°1788

Category: Viral hepatitis B/D: Clinical aspects except therapy

Title: The incidence and predictors of HCC in REVEAL chronic hepatitis B patients with incident spontaneous HBsAg loss

Presenter: Rachel Wen-Juei Jeng

Abstract n°1789

Category: Viral hepatitis B/D: Clinical aspects except therapy

Title: Characterization of the Liver Immune Microenvironment in Chronic HBV Infected Patient Liver Biopsies

Presenter: Nicholas Van Buuren

Abstract n°1810

Category: Viral hepatitis B/D: Clinical aspects except therapy

Title: A noninvasive model to predict liver histological lesions in chronic hepatitis B patients with persistently normal alanine aminotransferase and detectable viremia

Presenter: Qiankun Hu

Abstract n°1876

Category: Viral hepatitis B/D: Clinical aspects except therapy

Title: Novel shapelet patterns for time series classification (TSC) for AFP and ALT to predict HCC in patients with chronic hepatitis B on antiviral treatment

Presenter: Vicki Wing-Ki HUI

Abstract n°1892

Category: Viral hepatitis B/D: Clinical aspects except therapy

Title: The artificial intelligence-driven model for prediction of hepatocellular carcinoma development in chronic hepatitis B patients: Derivation and validation using 11,111 patients from Asian and Caucasian cohorts

Presenter: Hwi Young Kim

Abstract n°1982

Category: Viral hepatitis B/D: Clinical aspects except therapy

Title: Association between plasma miRNA-200-3p and transcriptional activity of hepatic cccDNA in chronic hepatitis B

Presenter: Vladimir Loukachov

Abstract n°1996

Category: Viral hepatitis B/D: Clinical aspects except therapy

Title: HBV reactivation can be predicted by combined highly-sensitive HBV markers: implications for an optimized management of HBsAg-negative/anti-HBc-positive oncohematological patients

Presenter: Mohammad Alkhatib

Abstract n°2134

Category: Viral hepatitis B/D: Clinical aspects except therapy

Title: The association of serum hepatitis B core antibody and liver inflammation in HBeAg-negative chronic hepatitis B patients with normal ALT and detectable HBV DNA

Presenter: Kefang Yao

Abstract n°2225

Category: Viral hepatitis B/D: Clinical aspects except therapy

Title: Predictive Immune Biomarkers of Persistent HBV DNA Suppression and Low Replicative State After Treatment Discontinuation in CHB Patients

Presenter: Henry LY Chan

Abstract n°2261

Category: Viral hepatitis B/D: Clinical aspects except therapy

Title: Changing demographic-clinic-pathologic profiles of newly diagnosed carriers of chronic hepatitis B virus infection across two decades: a single Italian reference center report

Presenter: Gabriele Ricco

Abstract n°2366

Category: Viral hepatitis B/D: Clinical aspects except therapy

Title: Nonalcoholic fatty liver disease in chronic hepatitis B patients: patients' characterization and impact on disease progression

Presenter: Fadi Abu Baker

Abstract n°43

Category: Viral hepatitis B/D: therapy

Title: Preliminary pharmacokinetics and safety in healthy volunteers of VIR-3434, a monoclonal antibody for the treatment of chronic hepatitis B infection

Presenter: Sneha V. Gupta

Abstract n°44

Category: Viral hepatitis B/D: therapy

Title: Safety and antiviral activity of VIR-2218, an X-targeting RNAi therapeutic, in participants with chronic hepatitis B infection: week 48 follow-up results

Presenter: Edward Gane

Abstract n°80

Category: Viral hepatitis B/D: therapy

Title: End-of-treatment HBsAg, HBcrAg and HBV RNA levels predict sustained response and HBsAg loss in chronic hepatitis B patients

Presenter: Sylvia Brakenhoff

Abstract n°111

Category: Viral hepatitis B/D: therapy

Title: One-year safety results of the Nuc-Stop Study, an open-label study on stopping antiviral therapy in HBeAg negative chronic hepatitis B

Presenter: Asgeir Johannessen

Abstract n°211

Category: Viral hepatitis B/D: therapy

Title: A phase 1 study evaluating the neutralizing, vaccinal monoclonal antibody VIR-3434 in participants with chronic hepatitis B virus infection

Presenter: Kosh Agarwal

Abstract n°247

Category: Viral hepatitis B/D: therapy

Title: On-treatment HBsAg kinetics can predict HBsAg loss after nucleos(t)ide analogues interruption in HBeAg negative patients

Presenter: Teresa Broquetas

Abstract n°397

Category: Viral hepatitis B/D: therapy

Title: Novel hepatitis B virus gene expression inhibitor in clinical development

Presenter: Vadim Bichko

Abstract n°430

Category: Viral hepatitis B/D: therapy

Title: High probability of reactive HBV-specific CD8 cells after stopping nucleos(t)ide analogue treatment forecast rapid HBsAg decrease in eAg(-) chronic hepatitis B

Presenter: Julia Peña Asensio

Abstract n°482

Category: Viral hepatitis B/D: therapy

Title: Viral response and safety following discontinuation of treatment with the core inhibitor vebicorvir and a nucleos(t)ide reverse transcriptase inhibitor in patients with HBeAg positive or negative chronic hepatitis B virus infection

Presenter: Edward Gane

Abstract n°636

Category: Viral hepatitis B/D: therapy

Title: VRON-0200, a therapeutic HBV vaccine with an intrinsic checkpoint inhibitor elicits broad CD8+ T cell responses and antiviral declines in preclinical studies

Presenter: Andrew Luber

Abstract n°655

Category: Viral hepatitis B/D: therapy

Title: Activation of inducible caspase 9 allows efficient depletion of adoptively transferred HBV-specific T cells

Presenter: Alexandre Klopp

Abstract n°691

Category: Viral hepatitis B/D: therapy

Title: Nucleos(t)ide analogue treatment is associated with lower risk of extrahepatic malignancy in chronic hepatitis B patients: A landmark study using nationwide claim data

Presenter: Sungwon CHUNG

Abstract n°715

Category: Viral hepatitis B/D: therapy

Title: One-year safety and efficacy of tenofovir alafenamide (TAF) in chronic hepatitis B (CHB): a Hellenic multicenter ReAl-life CLInical Study (HERACLIS TAF)

Presenter: George Papatheodoridis

Abstract n°774

Category: Viral hepatitis B/D: therapy

Title: A combination of gapmers and/or siRNA as potential gene therapy strategy against HBV infection: in vitro results.

Presenter: Maria Francesca Cortese

Abstract n°797

Category: Viral hepatitis B/D: therapy

Title: Tenofovir alafenamide in blocking mother-to-child transmission of hepatitis B virus: A multi-center,prospective clinical study

Presenter: Guorong Han

Abstract n°811

Category: Viral hepatitis B/D: therapy

Title: Unreliable estimation of fibrosis regression during treatment by liver stiffness measurement in patients with chronic hepatitis B

Presenter: Dong Ji

Abstract n°824

Category: Viral hepatitis B/D: therapy

Title: Preliminary on-treatment data from a phase 2 study evaluating VIR-2218 in combination with pegylated interferon alfa-2a in participants with chronic hepatitis B infection

Presenter: Man-Fung Yuen

Abstract n°853

Category: Viral hepatitis B/D: therapy

Title: A novel therapeutic vaccine achieves functional cure in a mouse model of chronic hepatitis B

Presenter: Renae Walsh

Abstract n°865

Category: Viral hepatitis B/D: therapy

Title: Immunoglobulin-free alternative strategy to prevent HBV mother to child transmission in Cambodia: preliminary results of the ANRS 12345 TA PROHM study

Presenter: Olivier Segeal

Abstract n°942

Category: Viral hepatitis B/D: therapy

Title: Discovery and characterization of EDP-721, a novel hepatitis B virus RNA destabilizer

Presenter: Michael Vaine

Abstract n°990

Category: Viral hepatitis B/D: therapy

Title: safety of tenofovir alafenamide administered before or in early phase of pregnancy in women with active chronic hepatitis b and the effectiveness in preventing perinatal hepatitis b virus infection: a multicenter prospective study

Presenter: Qing-Lei Zeng

Abstract n°1004

Category: Viral hepatitis B/D: therapy

Title: safety, tolerability and pharmacokinetics (pk) of single and multiple doses of alg-010133, an s-antigen transport inhibiting oligonucleotide polymer (stops) for the treatment of chronic hepatitis b

Presenter: Edward gane

Abstract n°1109

Category: Viral hepatitis B/D: therapy

Title: Baseline serum exosome-derived miRNAs predict HBeAg seroconversion in chronic hepatitis B patients treated with peginterferon

Presenter: Qiankun Hu

Abstract n°1196

Category: Viral hepatitis B/D: therapy

Title: ALG-125755, a Small Interfering RNA (siRNA) Against Hepatitis B Virus (HBV) Effectively Inhibits Hepatitis B Surface Antigen (HBsAg) Secretion in HBV Cell Models and the AAV-HBV Mouse Model

Presenter: Jin Hong

Abstract n°1240

Category: Viral hepatitis B/D: therapy

Title: Pharmacokinetics of ATI-2173, a novel active site polymerase inhibitor nucleotide, in a Phase 1b clinical trial

Presenter: Katherine Squires

Abstract n°1251

Category: Viral hepatitis B/D: therapy

Title: Phase 1 results for ATI-2173, a novel active site polymerase inhibitor nucleotide, in HBV-infected subjects

Presenter: Douglas Mayers

Abstract n°1270

Category: Viral hepatitis B/D: therapy

Title: Safety and efficacy of switching to besifovir dipivoxil maleate in virologically-suppressed chronic hepatitis B patients with tenofovir disoproxil fumarate: 24-week interim analysis

Presenter: Hyung Joon Yim

Abstract n°1286

Category: Viral hepatitis B/D: therapy

Title: No emergent core inhibitor resistance in patients with chronic hepatitis B virus infection treated with Vebicorvir in combination with a nucleos(t)ide reverse transcriptase inhibitor

Presenter: Man-Fung Yuen

Abstract n°1386

Category: Viral hepatitis B/D: therapy

Title: Capsid assembly modulator ALG-000111 and its prodrug ALG-000286 display excellent in vitro and in vivo antiviral activity

Presenter: Yannick Debing

Abstract n°1416

Category: Viral hepatitis B/D: therapy

Title: Pharmacokinetics and safety of JNJ-73763989, an RNA interference therapy for hepatitis B virus, in moderately hepatically impaired participants

Presenter: Thomas Kakuda

Abstract n°1419

Category: Viral hepatitis B/D: therapy

Title: First real-life experiences with 2 mg bulevirtide for the treatment of hepatitis delta - data from a tertiary reference centre in Germany

Presenter: Caroline Zöllner

Abstract n°1430

Category: Viral hepatitis B/D: therapy

Title: Short interfering RNA JNJ-3989 combination therapy in chronic hepatitis B shows potent reduction of all viral markers but no correlate was identified for HBsAg reduction and baseline factors

Presenter: Edward Gane

Abstract n°1448

Category: Viral hepatitis B/D: therapy

Title: Excellent virological and clinical responses maintained over 3 years of continuous Bulevirtide treatment in patients with HDV compensated cirrhosis and clinically significant portal hypertension

Presenter: Alessandro Loglio

Abstract n°1449

Category: Viral hepatitis B/D: therapy

Title: Tenofovir reduces the severity of COVID-19 infection in chronic hepatitis B patients

Presenter: BEATRIZ MATEOS MUÑOZ

Abstract n°1537

Category: Viral hepatitis B/D: therapy

Title: Induction of multifunctional CD8+ and CD4+ T cells using synthetic long peptides designed for therapeutic vaccination

Presenter: Diahann Jansen

Abstract n°1628

Category: Viral hepatitis B/D: therapy

Title: Comparison of hepatitis B virus relapses between hepatitis B e antigen-negative chronic hepatitis B patients who discontinue tenofovir disoproxil fumarate with or without switching to alafenamide

Presenter: Chien-Hung Chen

Abstract n°1661

Category: Viral hepatitis B/D: therapy

Title: Outcomes and characteristics of hepatocellular carcinomas (HCC) in Caucasian chronic hepatitis B (CHB) patients treated with long-term entecavir (ETV) or tenofovir disoproxil fumarate (TDF) therapy

Presenter: George Papatheodoridis

Abstract n°1699

Category: Viral hepatitis B/D: therapy

Title: Discovery and preclinical profile of VNRX-9945, a potent, broadly active core protein inhibitor for the treatment of hepatitis B virus (HBV) infection

Presenter: Glen Coburn

Abstract n°1775

Category: Viral hepatitis B/D: therapy

Title: GST-HG141, a novel clinical-stage hepatitis B virus capsid assembly modulator

Presenter: Vadim Bichko

Abstract n°1781

Category: Viral hepatitis B/D: therapy

Title: HCC incidence is low after HBsAg seroclearance in off-Nuc patients

Presenter: Rachel Wen-Juei Jeng

Abstract n°1791

Category: Viral hepatitis B/D: therapy

Title: Hepatic decompensation and hepatocellular carcinoma after stopping nucleos(t)ide analogue therapy: Results from a large, global, multi-ethnic cohort of patients with chronic hepatitis B (RETRACT-B study)

Presenter: Grishma Hirode

Abstract n°1837

Category: Viral hepatitis B/D: therapy

Title: HBsAg, anti-HBs and ALT kinetic characterization during NAP-based combination therapy of HBeAg negative chronic hepatitis B infection

Presenter: Harel Dahari

Abstract n°1841

Category: Viral hepatitis B/D: therapy

Title: Earlier and more frequent virological and clinical relapse after cessation of tenofovir disoproxil fumarate versus entecavir therapy: Results from a large, global, multi-ethnic cohort of chronic hepatitis B patients (RETRACT-B study)

Presenter: Hannah S.J. Choi

Abstract n°2089

Category: Viral hepatitis B/D: therapy

Title: HIF1a-mediated RelB/APOBEC3B downregulation allows Hepatitis B virus persistence

Presenter: Tobias Riedl

Abstract n°2106

Category: Viral hepatitis B/D: therapy

Title: T-cell engagers that bind HBV envelope proteins enable T cells to control the infection and to target hepatoma in mice

Presenter: Oliver Quitt

Abstract n°2243

Category: Viral hepatitis B/D: therapy

Title: Control of APOBEC3B induction and transcription-independent Hepatitis B virus episome decay by NF- κ B and miR-138-5p

Presenter: Suzanne Faure-Dupuy

Abstract n°2269

Category: Viral hepatitis B/D: therapy

Title: HBsAg, HBcrAg, and HBV RNA in outcomes and after NA discontinuation in HBeAg negative patients with chronic hepatitis B: results from the Toronto STOP Study

Presenter: Arif Sarowar

Abstract n°2283

Category: Viral hepatitis B/D: therapy

Title: Long-term Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) in Children with Chronic Hepatitis B (CHB): Final Results from a Placebo-Controlled Trial

Presenter: Mei-Hwei Chang

Abstract n°2299

Category: Viral hepatitis B/D: therapy

Title: Second generation Hepatitis B Virus core inhibitors ABI-H2158 and ABI-H3733 have enhanced potency and target coverage for both antiviral inhibition and covalently closed circular DNA establishment activities

Presenter: Dawei Cai

Abstract n°2338

Category: Viral hepatitis B/D: therapy

Title: Switching from tenofovir disoproxil fumarate and/or other oral antivirals to tenofovir alafenamide in virally suppressed chronic hepatitis B patients with hepatic impairment: final 2 year efficacy & safety results from a phase 2, open-label study

Presenter: Young-Suk Lim

Abstract n°2395

Category: Viral hepatitis B/D: therapy

Title: Switching from tenofovir disoproxil fumarate and/or other oral antivirals to tenofovir alafenamide in virally suppressed CHB patients with moderate or severe renal impairment or ESRD on HD: final week 96 efficacy & safety results from a phase 2 study

Presenter: Harry LA Janssen

Abstract n°2422

Category: Viral hepatitis B/D: therapy

Title: Safety, efficacy, & pharmacodynamic (PD) activity of 12 weeks treatment with oral RIG-I agonist, inarigivir (IRIG), plus 48 weeks of tenofovir alafenamide in adult patients with chronic hepatitis B: a phase 2 collaboration study

Presenter: Young-Suk Lim

Abstract n°2429

Category: Viral hepatitis B/D: therapy

Title: Safety and efficacy of oral TLR8 agonist, selgantolimod, in viremic adult patients with chronic hepatitis b

Presenter: Harry L.A. Janssen

Abstract n°68

Category: Viral hepatitis C: Clinical aspects except therapy

Title: Prospective independent confirmation of guideline defined hepatitis C screening strategies within the "Check-Up" examination in the primary care setting

Presenter: Johannes Wiegand

Abstract n°72

Category: Viral hepatitis C: Clinical aspects except therapy

Title: Hepatitis C in Connecticut Community Clinics: Measuring the Impact of the Project ECHO Model in Treatment in Primary Care

Presenter: Aaron Smith

Abstract n°131

Category: Viral hepatitis C: Clinical aspects except therapy

Title: From screening to therapy: Anti-HCV screening and linkage to care in a network of general practitioners and a private gastroenterology practice

Presenter: Johannes Wiegand

Abstract n°388

Category: Viral hepatitis C: Clinical aspects except therapy

Title: Increased screening, tailored access, linkage to care and treatment for PWUD through a patient centered program

Presenter: Alessandra Mangia

Abstract n°453

Category: Viral hepatitis C: Clinical aspects except therapy

Title: The impact of unrestricted access to direct-acting antiviral among 1001 incarcerated hepatitis C virus-infected patients

Presenter: YU JUN WONG

Abstract n°525

Category: Viral hepatitis C: Clinical aspects except therapy

Title: Pooling plasma samples for hepatitis C RNA detection: a strategy to expand access to diagnostics

Presenter: Federico Garcia Garcia

Abstract n°637

Category: Viral hepatitis C: Clinical aspects except therapy

Title: Achieving hepatitis C micro-elimination in prisons through High Intensive Test and Treat (HITT) interventions

Presenter: Sean Cox

Abstract n°649

Category: Viral hepatitis C: Clinical aspects except therapy

Title: Impact of extending DAAs availability in France: a five-year overview (2015-2019) of data from French administrative healthcare databases (SNDS)

Presenter: Stanislas Pol

Abstract n°690

Category: Viral hepatitis C: Clinical aspects except therapy

Title: depist C pharma, an innovative outreach HCV screening project in pharmacy for drug users and general population

Presenter: André-Jean Remy

Abstract n°694

Category: Viral hepatitis C: Clinical aspects except therapy

Title: Clinical features and comorbidities pattern of HCV infected migrants as compared to native patients in care in Italy: a real life evaluation in the PITER cohort

Presenter: Loreta Kondili

Abstract n°728

Category: Viral hepatitis C: Clinical aspects except therapy

Title: Late presentation for HCV care: time to target people with diabetes and/or hazardous alcohol use (ANRS CO22 HEPATHER cohort)

Presenter: Camelia Protopopescu

Abstract n°745

Category: Viral hepatitis C: Clinical aspects except therapy

Title: Simulations of HCV vaccine trials reveal opportunities to re-evaluate vaccine efficacy

Presenter: Harel Dahari

Abstract n°908

Category: Viral hepatitis C: Clinical aspects except therapy

Title: diagnostic accuracy of dried blood spot and plasma separation card samples for testing hepatitis c virus rna

Presenter: Agnes Malobela

Abstract n°951

Category: Viral hepatitis C: Clinical aspects except therapy

Title: High rates of hidden HCV infections among hospitalized patients aged 55-85

Presenter: Alessandra Mangia

Abstract n°955

Category: Viral hepatitis C: Clinical aspects except therapy

Title: Cost and effectiveness of treatment at Day 1 (Rapid Start) for hepatitis C and screening intensification in high-risk populations (T&T strategy) in France

Presenter: Christophe Hezode

Abstract n°983

Category: Viral hepatitis C: Clinical aspects except therapy

Title: Concordance of SVR 4-12-24 timepoints in an era of reduced sustained virologic response (SVR) determination

Presenter: Mark Sulkowski

Abstract n°1007

Category: Viral hepatitis C: Clinical aspects except therapy

Title: A comprehensive HBsAg-positive patient centered screening strategy targeting microelimination of Hepatitis C virus in Chongqing, China

Presenter: DACHUAN CAI

Abstract n°1029

Category: Viral hepatitis C: Clinical aspects except therapy

Title: Acute hepatitis C virus infection: A prospective ten years observational study of HCV-mono- and HCV/HIV-coinfected patients

Presenter: Christiana Graf

Abstract n°1186

Category: Viral hepatitis C: Clinical aspects except therapy

Title: Detection of active hepatitis C by two-step point-of-care based strategy and linkage to care among excluded people using a mobile unit in Madrid, Spain.

Presenter: Pablo Ryan

Abstract n°1339

Category: Viral hepatitis C: Clinical aspects except therapy

Title: Impact of the COVID-19 pandemic on hepatitis C virus screening in drug treatment settings in England and implications for testing protocols

Presenter: Shayon Salehi

Abstract n°1390

Category: Viral hepatitis C: Clinical aspects except therapy

Title: Automated Liver Function Testing in Identifying "Hard to Reach" Hepatitis B and C Patients

Presenter: Callum Livingstone

Abstract n°1397

Category: Viral hepatitis C: Clinical aspects except therapy

Title: Community-based linkage to care program targeting HCV elimination - Establishment of a model towards HCV elimination in china.

Presenter: Ming Li

Abstract n°1691

Category: Viral hepatitis C: Clinical aspects except therapy

Title: Feasibility and effectiveness of models of hepatitis C viraemia testing at harm reduction sites in Georgia: a prospective 3 arm study

Presenter: Maia Japaridze

Abstract n°1871

Category: Viral hepatitis C: Clinical aspects except therapy

Title: Screening, enhancement of access to care and prioritization of treatment of chronic hepatitis C infection in high-risk population in Hong Kong

Presenter: Lung Yi Mak

Abstract n°1966

Category: Viral hepatitis C: Clinical aspects except therapy

Title: Hepatitis C Elimination in the Netherlands (CELINE): nationwide retrieval of lost to follow-up chronic hepatitis C patients

Presenter: Marleen van Dijk

Abstract n°2048

Category: Viral hepatitis C: Clinical aspects except therapy

Title: Rapid point of care HCV testing allows high throughput HCV screening and rapid treatment uptake among PWID attending a medically supervised injecting room

Presenter: Michael Maclsaac

Abstract n°2095

Category: Viral hepatitis C: Clinical aspects except therapy

Title: Is elimination of hepatitis C across an entire prison network possible? A nurse-led test and treat model in 47 English prisons

Presenter: Hannah Alexander

Abstract n°2193

Category: Viral hepatitis C: Clinical aspects except therapy

Title: Evaluation of hepatitis C virus (HCV) core antigen assay from venepuncture compared to HCV RNA in plasma: a cohort study from Pakistan.

Presenter: Saeed Sadiq Hamid

Abstract n°2218

Category: Viral hepatitis C: Clinical aspects except therapy

Title: Cost-effectiveness of a novel point of care core antigen rapid diagnostic test for hepatitis C

Presenter: Madeline Adee

Abstract n°2352

Category: Viral hepatitis C: Clinical aspects except therapy

Title: Beating Hepatitis C together in challenging times: an evaluation of a multi-disciplinary approach to testing and treating homeless people temporarily housed during the COVID-19 pandemic

Presenter: Rebecca Wilkinson

Abstract n°2359

Category: Viral hepatitis C: Clinical aspects except therapy

Title: Hepatitis B and C screening in hospitalized SARS-CoV-2 patients

Presenter: Judith Gómez- Camarero

Abstract n°52

Category: Viral Hepatitis C: Post SVR and long term follow up

Title: Persistent long-term risk of liver related complications in hepatitis C virus patients after antiviral therapy - Data from the German Hepatitis C-Registry (DHC-R)

Presenter: Heiner Wedemeyer

Abstract n°404

Category: Viral Hepatitis C: Post SVR and long term follow up

Title: 12 weeks treatment of Sofosbuvir/Velpatasvir in HCV negative recipients receiving renal transplantation from HCV positive donors

Presenter: Xiaodong Yuan

Abstract n°578

Category: Viral Hepatitis C: Post SVR and long term follow up

Title: Long-term follow up in patients with hepatitis C virus treated with direct-acting-antiviral agents

Presenter: Paula Fernandez Alvarez

Abstract n°602

Category: Viral Hepatitis C: Post SVR and long term follow up

Title: Persistent perturbation of the circadian clock by chronic hepatitis C virus infection following cure with direct-acting antivirals

Presenter: Frank Jühling

Abstract n°666

Category: Viral Hepatitis C: Post SVR and long term follow up

Title: Characteristics and Survival Outcomes of Hepatocellular Carcinoma Developed After HCV SVR

Presenter: Ming-Lun Yeh

Abstract n°689

Category: Viral Hepatitis C: Post SVR and long term follow up

Title: Titer and breadth of anti-hepatitis C virus E2-glycoprotein antibodies in cirrhotic patients after direct antiviral agent therapy

Presenter: Daniel Sepúlveda-Crespo

Abstract n°697

Category: Viral Hepatitis C: Post SVR and long term follow up

Title: Incidence of liver and non-liver related events and mortality in a large cohort of HCV cirrhotics with an SVR to DAA: a 5-year single center study

Presenter: Roberta D'Ambrosio

Abstract n°717

Category: Viral Hepatitis C: Post SVR and long term follow up

Title: Non-invasive tests to predict liver-related events in a single-center cohort of 486 HCV cirrhotic patients treated with DAA

Presenter: Elisabetta Degasperi

Abstract n°862

Category: Viral Hepatitis C: Post SVR and long term follow up

Title: Mortality risk following HCV cure among people with HIV coinfection

Presenter: Naveed Janjua

Abstract n°881

Category: Viral Hepatitis C: Post SVR and long term follow up

Title: Gender differences in microRNAs profile in HIV patients after HCV eradication with DAAs: potential biased consequences

Presenter: Daniel Valle Millares

Abstract n°921

Category: Viral Hepatitis C: Post SVR and long term follow up

Title: PIVKA-II levels predict hepatocellular carcinoma development in caucasian HCV cirrhotic patients treated with DAAs

Presenter: Elisabetta Degasperi

Abstract n°975

Category: Viral Hepatitis C: Post SVR and long term follow up

Title: long-term effect of hcv eradication with direct acting antiviral (daas) therapy on egyptian patients with mixed cryoglobulinemias(mc)

Presenter: Mohamed Elnadry

Abstract n°1176

Category: Viral Hepatitis C: Post SVR and long term follow up

Title: Hepatitis C virus eradication improves cognition in patients with and without cirrhosis: results from a real-life prospective study.

Presenter: Luis Ibañez

Abstract n°1247

Category: Viral Hepatitis C: Post SVR and long term follow up

Title: New onset steatosis but not persistent steatosis prevents hepatic fibrosis improvement after viral eradication by direct-acting antiviral therapy (DAAs) in patients with chronic hepatitis C: evaluation by CAP and LSM

Presenter: Annalisa Cespiati

Abstract n°1404

Category: Viral Hepatitis C: Post SVR and long term follow up

Title: Metabolomic changes in HIV/HCV coinfecting patients after DAAs therapy

Presenter: Óscar Brochado-Kith

Abstract n°1415

Category: Viral Hepatitis C: Post SVR and long term follow up

Title: Usefulness of dried blood spot samples for HCV genotyping to inform retreatment after recurrent viremia in people who inject drugs in the real world

Presenter: Elisa Martró

Abstract n°1542

Category: Viral Hepatitis C: Post SVR and long term follow up

Title: Metabolic comorbidities reduce the improvement of procoagulant imbalance in non-cirrhotic patients with chronic hepatitis C (CHC) after viral eradication with direct-acting antiviral agents (DAAs)

Presenter: Giordano Sigon

Abstract n°1561

Category: Viral Hepatitis C: Post SVR and long term follow up

Title: Risk of hepatocellular carcinoma after HCV eradication: capturing the role of portal hypertension

Presenter: Elton Dajti

Abstract n°1918

Category: Viral Hepatitis C: Post SVR and long term follow up

Title: The impact of hepatitis C virus eradication on hepatocarcinogenesis in haemophiliacs

Presenter: Yosuke Inukai

Abstract n°1919

Category: Viral Hepatitis C: Post SVR and long term follow up

Title: Long term follow-up in HCV infected patients with end stage chronic kidney disease after DAA therapy

Presenter: Joan Martinez-Camprecios

Abstract n°2008

Category: Viral Hepatitis C: Post SVR and long term follow up

Title: Liver stiffness measurements for the prediction of liver-related outcomes in chronic hepatitis C patients after viral elimination

Presenter: Yen-Chun Liu

Abstract n°2418

Category: Viral Hepatitis C: Post SVR and long term follow up

Title: Hepatitis C virus genotype 3 is associated with high risk of de novo portal vein thrombosis in cirrhotic patients after successful antiviral therapy: Russian long-term single center experience

Presenter: Ekaterina Nabatchikova

Abstract n°51

Category: Viral hepatitis C: Therapy and resistance

Title: Aiming for HCV elimination - Optimizing DAA therapy by characterisation of patients lost to follow up (LTFU) in a large real world setting - Data from the German Hepatitis C-Registry (DHC-R)

Presenter: Stefan Christensen

Abstract n°81

Category: Viral hepatitis C: Therapy and resistance

Title: Economic consequences of anti-HCV treatment of patients diagnosed through screening in Italy: a prospective modeling analysis.

Presenter: Claudia Simonelli

Abstract n°153

Category: Viral hepatitis C: Therapy and resistance

Title: Prevalence and origin of rare HCV Genotypes in DAA-naive and DAA-experienced patients

Presenter: Julia Dietz

Abstract n°377

Category: Viral hepatitis C: Therapy and resistance

Title: Risk of multiple drug-drug interactions (DDIs) in HCV patients receiving pangenotypic DAAs (pDAAs): A complex drug interaction scenario first time evaluated in German patients

Presenter: Frank Tacke

Abstract n°468

Category: Viral hepatitis C: Therapy and resistance

Title: Direct antivirals can achieve a cure in all patients with chronic hepatitis C due to genotype 5. A French multicentre study.

Presenter: Armand Abergel

Abstract n°773

Category: Viral hepatitis C: Therapy and resistance

Title: Frequency and impact of potential multiple drug-drug interactions (DDIs) associated with pangenotypic direct-acting antivirals in patients receiving opioid substitution therapy

Presenter: Frank Tacke

Abstract n°795

Category: Viral hepatitis C: Therapy and resistance

Title: Peer support in a national hepatitis C elimination program - pseudo-randomised analysis of impact in 30,729 patients

Presenter: Davina Jugnarain

Abstract n°815

Category: Viral hepatitis C: Therapy and resistance

Title: Efficacy and safety of 8- or 12 weeks of glecaprevir/pibrentasvir in patients with signs of portal hypertension

Presenter: Robert BROWN

Abstract n°987

Category: Viral hepatitis C: Therapy and resistance

Title: SH229 plus daclatasvir for treatment of chronic hepatitis C virus infection in China: a single-arm, open-label, phase 3 study

Presenter: Rui Hua

Abstract n°1307

Category: Viral hepatitis C: Therapy and resistance

Title: High rate of early HCV reinfection among PWID with high-risk practices and re-treatment efficacy

Presenter: Sabela Lens

Abstract n°1508

Category: Viral hepatitis C: Therapy and resistance

Title: Injecting network structure determines the most efficient strategy to achieve Hepatitis C elimination in people who inject drugs

Presenter: ryan buchanan

Abstract n°1533

Category: Viral hepatitis C: Therapy and resistance

Title: FULL DOSE SOFOSBUVIR - VELPATASVIR IN CHRONIC HEPATITIS C IN PATIENTS WITH END STAGE RENAL DISEASE.

Presenter: AADIL ASHRAF

Abstract n°1553

Category: Viral hepatitis C: Therapy and resistance

Title: Progress towards achieving hepatitis C elimination in the country of Georgia, April 2015-December 2020

Presenter: Tengiz Tsertsvadze

Abstract n°1872

Category: Viral hepatitis C: Therapy and resistance

Title: A costing analysis of a state-wide, nurse-led hepatitis C treatment model in prison

Presenter: Anna Palmer

Abstract n°1962

Category: Viral hepatitis C: Therapy and resistance

Title: Validation of a simple score to identify patients who can safely use protease inhibitor-based therapy for HCV infection

Presenter: Lisette Krassenburg

Abstract n°2020

Category: Viral hepatitis C: Therapy and resistance

Title: Good practice hepatitis C screening and linkage to care initiatives at the SLTC Summit 2020: three out of four diagnosed patients able to start direct-acting antiviral treatment

Presenter: Joaquín Cabezas

Abstract n°2021

Category: Viral hepatitis C: Therapy and resistance

Title: Deferred direct-acting antiviral treatment in kidney transplantation from HCV-viremic donors into HCV-negative recipients.

Presenter: GIULIA PAGANO

Abstract n°2138

Category: Viral hepatitis C: Therapy and resistance

Title: Safety and efficacy of direct acting antiviral therapy for chronic HCV infection in elderly people

Presenter: Daniela Maggi

Abstract n°2191

Category: Viral hepatitis C: Therapy and resistance

Title: Directly observed therapy for hepatitis C alongside opioid agonist therapy as an effective microelimination strategy for PWIDs with a high risk for non-adherence in Vienna, Austria

Presenter: Michael Schwarz

Abstract n°2205

Category: Viral hepatitis C: Therapy and resistance

Title: Delivering elimination: rapid scale-up of hepatitis c virus treatment among people who inject drugs in Tayside, Scotland

Presenter: Christopher Byrne

Abstract n°2240

Category: Viral hepatitis C: Therapy and resistance

Title: Real-time utility of response-guided DAA therapy for hepatitis C based on a mathematical modeling approach:database formation and machine learning methods

Presenter: Harel Dahari

Abstract n°2275

Category: Viral hepatitis C: Therapy and resistance

Title: Prevalence of resistance associated substitutions in hepatitis C virus NS5A against direct acting antivirals

Presenter: Zain Ul Abideen

Abstract n°2295

Category: Viral hepatitis C: Therapy and resistance

Title: Amino acid substitutions associated with treatment failure of hepatitis C virus infection

Presenter: Carlos García-Crespo

Abstract n°2306

Category: Viral hepatitis C: Therapy and resistance

Title: DAA THERAPY IN HCV-INFECTED EGYPTIAN CHILDREN: REAL-LIFE MODEL FROM A MULTICENTRE PROGRAM SUPPORTED BY AN NGO

Presenter: Manal Hamdy El-Sayed

Abstract n°2320

Category: Viral hepatitis C: Therapy and resistance

Title: Efficacy and Safety of Sofosbuvir\Ledipasvir Combination or Nitazoxanide in Treatment of COVID-19: A Placebo-Controlled, Randomized Clinical Trial

Presenter: Mohammed Medhat